2025/10/23 更新

写真a

イチハラ　エイキ
市原　英基
ICHIHARA Eiki
所属
学術研究院医療開発領域 准教授
職名
准教授
外部リンク

学位

  • 医学博士 （ 2010年3月   岡山大学 ）

  • 医学博士 （ 2010年3月   岡山大学大学院医歯薬学総合研究科 ）

研究キーワード

  • 薬剤tolerance

  • 薬剤耐性

  • 肺癌

  • 免疫チェックポイント阻害薬

  • 分子標的治療

研究分野

  • ライフサイエンス / 呼吸器内科学

学歴

  • 岡山大学   Graduate School of Medicine , Dentistry and Pharmaceutical Sciences  

    2006年4月 - 2010年3月

    　 詳細を見る

  • 岡山大学   Medical School   Faculty of Medicine

    1995年4月 - 2001年3月

    　 詳細を見る

    国名： 日本国

    researchmap

経歴

  • 岡山大学病院   腫瘍センター   准教授、腫瘍センター長、緩和支持医療科長

    2025年4月

    　 詳細を見る

  • 岡山大学病院   腫瘍センター   講師

    2023年10月 - 2025年3月

    　 詳細を見る

  • 岡山大学病院   呼吸器・アレルギー内科   講師

    2018年1月 - 2023年9月

    　 詳細を見る

  • 岡山大学病院   呼吸器・アレルギー内科   助教

    2017年4月 - 2017年12月

    　 詳細を見る

  • 岡山大学   大学院医歯薬学総合研究科   助教

    2016年2月 - 2017年3月

    　 詳細を見る

  • Vanderbilt Ingram Cancer Center   Postdoctoral Fellow

    2013年7月 - 2016年1月

    　 詳細を見る

▼全件表示

所属学協会

▼全件表示

委員歴

  • 日本がん治療認定医機構   教育委員会委員  

    2024年1月 - 現在   

    　 詳細を見る

  • 日本がん治療認定医機構   教育委員会 委員  

    2024年1月 - 2024年12月   

    　 詳細を見る

  • 日本肺癌学会   利益相反委員 副委員長  

    2022年12月 - 現在   

    　 詳細を見る

  • 日本呼吸器学会 中国・四国支部 事務局  

    2022年7月 - 現在   

    　 詳細を見る

  • 日本臨床腫瘍学会   COVID-19関連教育事業WG 委員  

    2022年2月 - 2024年9月   

    　 詳細を見る

  • 日本肺癌学会 中国・四国支部   事務局  

    2021年7月 - 現在   

    　 詳細を見る

  • 日本呼吸器学会   学術講演会プログラム委員会 委員  

    2021年4月 - 2022年3月   

    　 詳細を見る

  • 日本呼吸器学会   COVID-19 診療 expert opinion ワーキング委員会 委員  

    2020年12月 - 2024年3月   

    　 詳細を見る

  • 日本肺癌学会   評議員  

    2020年11月 - 現在   

    　 詳細を見る

  • 日本肺癌学会   利益相反委員  

    2020年11月 - 現在   

    　 詳細を見る

  • 日本臨床腫瘍学会   がん関連３学会合同連携委員会 新型コロナウイルス(COVID-19)対策ワーキンググループ委員（WG）  

    2020年4月 - 現在   

    　 詳細を見る

  • 日本呼吸器学会   代議員  

    2019年8月 - 現在   

    　 詳細を見る

  • 日本呼吸器学会   腫瘍学術部会 委員  

    2019年4月 - 現在   

    　 詳細を見る

    団体区分：学協会

    researchmap

  • 日本肺癌学会   臨床研究推進委員  

    2018年12月 - 現在   

    　 詳細を見る

  • 日本肺癌学会   用語委員  

    2018年12月 - 2020年11月   

    　 詳細を見る

  • 日本がん治療認定医機構   教育委員会協力員  

    2018年11月   

    　 詳細を見る

  • 日本がん治療学会   G-CSF適正使用ガイドライン委員  

    2018年8月 - 現在   

    　 詳細を見る

  • 日本呼吸器学会 中国四国支部   代議員  

    2017年 - 現在   

    　 詳細を見る

  • 日本肺癌学会 中国・四国支部   評議員  

    2016年7月 - 現在   

    　 詳細を見る

  • 日本呼吸器学会   間質性肺炎合併肺癌に関するステートメント編集委員  

    2016年3月 - 2019年11月   

    　 詳細を見る

  • 日本臨床腫瘍学会   協議員  

    2013年8月 - 現在   

    　 詳細を見る

  • 日本内科学会中国支部   評議員  

    2012年 - 現在   

    　 詳細を見る

▼全件表示

 

論文

  • Efficacy and safety of dose-dense chemotherapy for early-stage breast cancer under prophylactic pegfilgrastim administration: a systematic review and meta-analysis from clinical practice guidelines for the use of G-CSF 2022.

    Takamichi Yokoe, Tetsuhiro Yoshinami, Kazuki Nozawa, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano

    International journal of clinical oncology   30 ( 4 )   674 - 683   2025年4月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: In early-stage breast cancer, dose-dense chemotherapy, which involves the administration of standard doses at shorter intervals, is safer when administered with granulocyte colony-stimulating factor (G-CSF) to mitigate chemotherapy-induced neutropenia. This study aimed to thoroughly evaluate the advantages and disadvantages of dose-dense regimens based on the use of G-CSF. METHODS: A systematic review was conducted according to the "Minds Handbook for Clinical Practice Guideline Development" using PubMed, Ichushi-Web, and the Cochrane Library databases. Randomized controlled trials (RCTs) and cohort studies assessing dose-dense chemotherapy with prophylactic pegfilgrastim administration in early-stage breast cancer were included. Outcomes included overall survival, event-free survival, incidence of febrile neutropenia, quality of life (QOL), and pain. Meta-analyses were performed on outcomes with sufficient data. RESULTS: Our literature search identified 23 RCTs. Overall survival and event-free survival showed a trend favoring dose-dense therapy (hazard ratio, 0.90, 0.90; 95% confidence interval [CI] 0.78 - 1.03, 0.80 - 1.01; p = 0.13; 0.07, respectively). The incidence of febrile neutropenia was similar between the groups (odds ratio, 0.90; 95% CI 0.58 - 1.40; p = 0.65). Mortality due to infection could not be compared owing to the small number of events. Pain increased with dose-dense therapy (odds ratio 2.57; 95% CI 1.00 - 6.62; p = 0.05), likely from G-CSF-induced bone pain. Only one study examined QOL, showing a decline with chemotherapy that recovered after treatment. CONCLUSIONS: Dose-dense chemotherapy trended toward improved survival outcomes without increasing the risk of infection, although pain increased. Further research should identify the specific subgroups that most benefit from dose-dense regimens. More data are needed on the impact on QOL.

    DOI： 10.1007/s10147-025-02716-2

    PubMed

    researchmap

  • Influence of Educational Films on Antiviral Prescription for COVID-19: Insights from Web-Based Survey in Japan. 国際誌

    Kosaku Komiya, Akihiko Hagiwara, Yuichiro Shindo, Kazufumi Takamatsu, Naoki Nishimura, Yukako Takechi, Eiki Ichihara, Takahiro Takazono, Shinyu Izumi, Shimpei Gotoh, Seiichiro Sakao, Takehiro Izumo, Kazuko Yamamoto, Kazuhiro Yatera, Hiroshi Kakeya, Yoko Shibata, Keisuke Tomii, Hironori Sagara, Yuka Sasaki, Toyohiro Hirai, Akihito Yokoyama, Hiroshi Mukae, Takashi Ogura

    Antibiotics (Basel, Switzerland)   14 ( 3 )   2025年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Background: Prescribing antiviral agents for severe acute respiratory syndrome coronavirus 2 requires careful consideration based on the patient's risk factors for severe disease progression and their vaccination status. However, effective interventions ensuring the appropriate use of antiviral agents by physicians have yet to be fully established. Thus, this study evaluated the impact of an educational film on antiviral prescription rates for coronavirus disease 2019 (COVID-19). Methods: This prospective, nationwide, web-based survey enrolled 1500 physicians. They were instructed to view a short educational film and assess the necessity of prescribing antiviral agents in 16 fictitious scenarios featuring adult patients with COVID-19 with varying risk factors for severe disease and vaccination statuses. We compared the antiviral prescription rates before and after viewing the educational film. Results: There was a significant increase in the antiviral prescription rates after viewing the educational film, particularly nirmatrelvir/ritonavir prescribed in cases involving immunocompromised patients (from 31.3% to 49.4%) and those with obesity (from 15.1% to 33.7%) who were unvaccinated and had no risk of drug interactions. However, viewing the educational film made little to no impact on the prescription rates for the patients with hypertension and hyperlipidemia or those with no underlying conditions. Conclusions: Short educational films may promote the appropriate use of antiviral agents for COVID-19. However, their impact on altering prescription behavior appears limited and varies according to the clinical context.

    DOI： 10.3390/antibiotics14030276

    PubMed

    researchmap

  • Efficacy of amivantamab, a bi-specific antibody targeting EGFR and MET, in ALK-rearranged non-small-cell lung cancer cell lines. 国際誌

    Tatsuya Nishi, Ayako Morita, Naofumi Hara, Go Makimoto, Kiichiro Ninomiya, Masanori Fujii, Kammei Rai, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Eiki Ichihara

    Lung cancer (Amsterdam, Netherlands)   201   108415 - 108415   2025年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are highly effective in treating ALK-rearranged non-small-cell lung cancer (NSCLC). However, at least 40% of patients develop acquired resistance during treatment. Adaptive or acquired resistance to ALK TKIs could be mediated through epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) signaling. Sixteen percent of acquired resistance cases are linked to bypass signaling. METHODS: In this study, we evaluated the effects of amivantamab, a bi-specific antibody targeting both EGFR and MET, on ALK-rearranged NSCLC cells. We investigated the effect of amivantamab on the ALK-rearranged NSCLC cell lines H3122, ABC-19, and ABC-11. RESULTS: Combining alectinib with amivantamab resulted in greater inhibition of cell growth inhibition in H3122 and ABC-19 cells compared to alectinib alone, but not in ABC-11 cells. EGFR TKI erlotinib showed similar efficacy in H3122 and ABC-19 cells, whereas MET TKI tepotinib was ineffective in both, suggesting that the efficacy of amivantamab is through EGFR inhibition. Unlike H3122 and ABC-19 cells, ABC-11 cells were resistant to EGFR/MET signaling inhibition. Interestingly, amivantamab enhanced alectinib efficacy against ABC-11 cells in the presence of peripheral blood mononuclear cells (PBMCs), despite showing no effect alone without PBMCs, suggesting action through non-signal inhibitory mechanisms. Finally, we treated alectinib-resistant cellswith alectinib, with or without amivantamab, and found that amivantamab restored the sensitivity of these cells to alectinib. CONCLUSION: The bi-specific antibody amivantamab, which targets EGFR and MET, enhanced the efficacy of alectinib through both signal and non-signal inhibitory mechanisms in ALK-rearranged NSCLC cells.

    DOI： 10.1016/j.lungcan.2025.108415

    PubMed

    researchmap

  • Multicenter, open-label, randomized, controlled study to test the utility of electronic patient-reported outcome monitoring in patients with unresectable advanced cancers or metastatic/recurrent solid tumors. 国際誌

    Naruto Taira, Naomi Kiyota, Yuichiro Kikawa, Eiki Ichihara, Kyoko Kato, Kaoru Kubota, Ryosuke Tateishi, Akinobu Nakata, Keiichiro Nakamura, Yukiya Narita, Katsuyuki Hotta, Hiroji Iwata, Akihiko Gemma, Kojiro Shimozuma, Kei Muro, Tetsuya Iwamoto, Yuki Takumoto, Takeru Shiroiwa, Takashi Fukuda, Takuhiro Yamaguchi, Yasuhiro Hagiwara, Hironobu Minami

    Japanese journal of clinical oncology   2025年2月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Electronic patient-reported outcome (ePRO) monitoring for patients undergoing cancer chemotherapy may provide qualified and early detection of adverse events or disease-related symptoms, leading to improved patient care. The aim of this study is to examine whether addition of ePRO monitoring to routine medical care contributes to improved overall survival and quality of life of cancer patients undergoing chemotherapy. Patients with unresectable advanced cancers or metastatic/recurrent solid tumors receiving systemic chemotherapy will be randomized to an ePRO monitoring group and a usual care group. The ePRO group will conduct weekly symptom monitoring using an electronic device after study enrollment until the end of the study. Monitoring results will be returned to medical personnel and used as information for patient care. The primary endpoints are overall survival and health related quality of life. The initial target sample size for the study was 1500 patients. However, due to delays in enrollment, the target was readjusted to 500 patients. Enrollment has been completed, and the study is now in the follow-up phase.

    DOI： 10.1093/jjco/hyaf033

    PubMed

    researchmap

  • Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study

    Katsuyuki Hotta, Sho Saeki, Shinya Sakata, Masafumi Yamaguchi, Daijiro Harada, Akihiro Bessho, Kentaro Tanaka, Koji Inoue, Koji Inoue, Kenichi Gemba, Toshio Kubo, Akiko Sato, Eiki Ichihara, Hiromi Watanabe, Junji Kishimoto, Yoshiyuki Shioyama, Kuniaki Katsui, Kenji Sugio, Katsuyuki Kiura

    International Journal of Clinical Oncology   30 ( 3 )   497 - 503   2025年2月

    　詳細を見る

    掲載種別：研究論文（学術雑誌）   出版者・発行元：Springer Science and Business Media LLC  

    Abstract

    Background

    We previously showed the 2-year OS rate, the primary endpoint, of 90% in a phase II trial of gefitinib induction followed by chemoradiotherapy (CRT) in unresectable, stage III, EGFR-mutant, non-small-cell lung cancer (NSCLC). However, neither long-term survival data nor late-phase adverse event profiles have been presented.

    Patients and methods

    Patients with unresectable, EGFR-mutant, stage III NSCLC were administered gefitinib monotherapy for 8 weeks. After confirming no disease progression during induction therapy, cisplatin and docetaxel on days 1, 8, 29, and 36 with concurrent radiotherapy at a total dose of 60 Gy were subsequently administered.

    Results

    In the enrolled twenty patients, the 5-year OS rate and median survival time were 70.0% [95% confidence interval: 45.1–85.3] and 5.5 years [4.91-NE], respectively, whereas 5-year PFS rate and median PFS time were 15.0% (3.7–33.5) and 1.4 years [0.69–2.29], respectively. Efficacy did not seem influenced even if radiation field was re-planed in response to the effect of gefitinib induction. As for late adverse events, pulmonary fibrosis occurred in 7 patients (35%). The median time from completion of CRT to the occurrence of the event was 245 days. All were grade 1, and there was no evidence of cavitation of the lesions or chronic infections such as Aspergillus infection during the course of the disease. One case of small cell lung cancer occurred during the period.

    Conclusions

    With longer follow-up time, we demonstrated favorable efficacy with tolerable toxicity profiles in the EGFR-TKI induction followed by standard CRT in EGFR-mutant, stage III, NSCLC.

    Trial registration numbers

    UMIN00005086. https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&recptno=R000006047&type=summary&language=EjRCTs071180036. https://jrct.niph.go.jp/latest-detail/jRCTs071180036

    DOI： 10.1007/s10147-025-02696-3

    researchmap

    その他リンク： https://link.springer.com/article/10.1007/s10147-025-02696-3/fulltext.html

  • A Prompt Diagnosis and Treatment of a Case of Nuclear Protein of the Testis Carcinoma Characterized by a Bronchial Lesion and High Serum Alpha-fetoprotein Level Following Genomic Testing.

    Hiroaki Matsuura, Go Makimoto, Naohiro Oda, Kiichiro Ninomiya, Hisao Higo, Masanori Fujii, Kammei Rai, Eiki Ichihara, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda

    Internal medicine (Tokyo, Japan)   63 ( 19 )   2655 - 2660   2024年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Nuclear protein of the testis carcinoma (NUTC) is a rare and aggressive malignancy. We herein report a case of NUTC in the lung characterized by a bronchial lesion and elevated alpha-fetoprotein levels. A 35-year-old Japanese man presented to our institution with suspected advanced lung cancer based on a histological examination. Subsequently, next-generation sequencing (NGS) yielded a positive BRD4-NUTM1 fusion. In addition, positive NUT immunostaining of the lung biopsy specimen confirmed NUTC in the lungs. Systemic chemotherapy and radiotherapy showed a temporary response, with decreased serum alpha-fetoprotein levels. We highlight this case of a prompt diagnosis by NGS of NUTC in a young individual with a rapidly progressing tumor.

    DOI： 10.2169/internalmedicine.2938-23

    PubMed

    researchmap

  • A novel molecular target, superoxide dismutase 1, in ALK inhibitor-resistant lung cancer cells, detected through proteomic analysis. 国際誌

    Noriko Miyake, Nobuaki Ochi, Masami Takeyama, Hideko Isozaki, Eiki Ichihara, Hiromichi Yamane, Takuya Fukazawa, Yasunari Nagasaki, Tatsuyuki Kawahara, Hidekazu Nakanishi, Akio Hiraki, Katsuyuki Kiura, Nagio Takigawa

    Experimental cell research   442 ( 2 )   114266 - 114266   2024年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUNDS: To the best of our knowledge, there are no reports of proteomic analysis for the identification of unknown proteins involved in resistance to anaplastic lymphoma kinase (ALK) inhibitors. In this study, we investigated the proteins involved in resistance to alectinib, a representative ALK inhibitor, through proteomic analysis and the possibility of overcoming resistance. METHODS: An ALK-positive lung adenocarcinoma cell line (ABC-11) and the corresponding alectinib-resistant cell line (ABC-11/CHR2) were used. Two-dimensional difference gel electrophoresis (2D DIGE) was performed; the stained gel was scanned and the spots were analyzed using DeCyder TM2D 7.0. Mass spectrometry (MS) with the UltrafleXtreme matrix-assisted laser desorption ionization-tandem time-of-flight (MALDI-TOF/TOF) MS system was performed. For the MS/MS analysis, the samples were spotted on an AnchorChipTM 600 TF plate. The peptide masses obtained in the reflector positive mode were acquired at m/z of 400-6000. MS/MS data were searched against the NCBI protein databases. Growth inhibition was measured using an MTT assay. The isobologram and combination index were calculated based on the median-effect analysis. Western blotting was performed using antibodies, including superoxide dismutase (SOD) 1, MET, ERK, PARP, AKT, and BRCA1. RESULTS: The 2D DIGE for ABC-11 and ABC-11/CHR2 showed different expression levels in about 2000 spots. SOD was identified from spots highly expressed in resistant strains. Western blotting also confirmed SOD1 overexpression in ABC-11/CHR2. siSOD1 enhanced the growth inhibitory effects of alectinib, increased cleaved PARP levels, and decreased pERK, pAKT, and BRCA1 levels with a combination of alectinib. In addition, the combination of LCS-1, an SOD1 inhibitor, and alectinib synergistically suppressed the growth in ABC-11/CHR2, but not in ABC-11. CONCLUSIONS: SOD1 overexpression is thought to be a mechanism for alectinib resistance, suggesting the possibility of overcoming resistance using SOD1 inhibitors.

    DOI： 10.1016/j.yexcr.2024.114266

    PubMed

    researchmap

  • A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.

    Kiyotaka Yoh, Koichi Azuma, Hidetoshi Hayashi, Makoto Nishio, Kenichi Chikamori, Eiki Ichihara, Yasutaka Watanabe, Takayuki Asato, Tadayuki Kitagawa, Robert J Fram, Yuichiro Ohe

    International journal of clinical oncology   29 ( 10 )   1461 - 1474   2024年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: Mobocertinib is a novel, synthetic, orally administered tyrosine kinase inhibitor that inhibits many activated forms of epidermal growth factor receptor (EGFR), including those containing exon 20 insertion (ex20ins) mutations. This study aimed to assess the efficacy of mobocertinib in Japanese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR ex20ins mutations. METHODS: This was a phase 2, open-label study. Patients with NSCLC harboring EGFR ex20ins mutations who had not had previous systemic treatment received mobocertinib 160 mg once daily. The primary endpoint was the confirmed objective response rate. A planned interim analysis was completed for the first 14 patients with a centrally confirmed EGFR ex20ins mutation, with enrollment stopped if the number of patients with an objective response was five or fewer. RESULTS: In total, 33 patients were enrolled into the study (63.6% women; median age: 66 years). At the interim analysis, the objective response rate evaluated by a central independent review committee was 28.6% (4/14, 90% confidence interval: 10.4-54.0); therefore, enrollment was stopped for futility. In the full analysis set, the objective response rate was 18.2% (6/33, 95% confidence interval: 7.0-35.5); of the six responders, one patient (3.0%) had a complete response and five patients (15.2%) had partial responses. The most common treatment-related adverse events were diarrhea, paronychia, stomatitis, and nausea. CONCLUSION: Although study enrollment was terminated early owing to futility, our results showed modest activity of mobocertinib in Japanese patients with NSCLC with EGFR ex20ins mutations with no additional safety concerns.

    DOI： 10.1007/s10147-024-02588-y

    PubMed

    researchmap

  • A Case of Single-lung Transplant in a Patient with Mycobacterium avium Pulmonary Disease Successfully Treated with Amikacin Liposome Inhalation Suspension.

    Taichi Ozeki, Hisao Higo, Hiroki Omori, Shunta Mori, Shin Tanaka, Go Makimoto, Kiichiro Ninomiya, Akihiko Taniguchi, Masanori Fujii, Kentaro Miyoshi, Kammei Rai, Eiki Ichihara, Kadoaki Ohashi, Seiichiro Sugimoto, Katsuyuki Hotta, Masahiro Tabata, Shinichi Toyooka, Yoshinobu Maeda, Nobuaki Miyahara

    Internal medicine (Tokyo, Japan)   2024年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    A 55-year-old man presented to our hospital with idiopathic pulmonary fibrosis (IPF). He was registered with the Japan Organ Transplant Network the following year due to disease progression. Treatment with clarithromycin, ethambutol, and rifampicin for complications of Mycobacterium avium pulmonary disease was initiated, but sputum conversion could not be achieved. The administration of an amikacin liposome inhalation suspension (ALIS) resulted in sputum conversion, and single-lung transplantation was performed. ALIS therapy was continued after lung transplantation, and no M. avium disease was observed for 15 months. ALIS may cause M. avium pulmonary disease with additional indications for lung transplantation.

    DOI： 10.2169/internalmedicine.3854-24

    PubMed

    researchmap

  • Response to Imatinib in a Patient With Gastric Adenocarcinoma With KIT Q556_K558 In-Frame Deletion: A Case Report. 国際誌

    Kiichiro Ninomiya, Daisuke Ennishi, Kunio Okamoto, Midori Ando, Satoko Nakamura, Shuta Tomida, Yoshiyuki Ayada, Go Makimoto, Eiki Ichihara, Natsuko Okita, Shinichi Toyooka, Yoshinobu Maeda, Masahiro Tabata

    JCO precision oncology   8   e2400228   2024年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Imatinib may be a useful targeted agent for patients with advanced gastric adenocarcinoma who have KIT mutations.

    DOI： 10.1200/PO.24.00228

    PubMed

    researchmap

  • Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer. 国際誌

    James Chih-Hsin Yang, Dae Ho Lee, Jong-Seok Lee, Yun Fan, Filippo de Marinis, Eiji Iwama, Takako Inoue, Jerónimo Rodríguez-Cid, Li Zhang, Cheng-Ta Yang, Emmanuel de la Mora Jimenez, Jianying Zhou, Maurice Pérol, Ki Hyeong Lee, David Vicente, Eiki Ichihara, Gregory J Riely, Yiwen Luo, Diana Chirovsky, M Catherine Pietanza, Niyati Bhagwati, Shun Lu

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology   JCO2302747   2024年8月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    PURPOSE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR-mutant, metastatic non-small cell lung cancer (NSCLC); however, most patients experience disease progression. We report results from the randomized, double-blind, phase III KEYNOTE-789 study of pemetrexed and platinum-based chemotherapy with or without pembrolizumab for TKI-resistant, EGFR-mutant, metastatic nonsquamous NSCLC (ClinicalTrials.gov identifier: NCT03515837). METHODS: Adults with pathologically confirmed stage IV nonsquamous NSCLC, documented DEL19 or L858R EGFR mutation, and progression after EGFR-TKI treatment were randomly assigned 1:1 to 35 cycles of pembrolizumab 200 mg or placebo once every 3 weeks plus four cycles of pemetrexed and carboplatin or cisplatin once every 3 weeks and then maintenance pemetrexed. Dual primary end points were progression-free survival (PFS) and overall survival (OS). Final PFS testing was completed at the second interim analysis (IA2; data cutoff, December 3, 2021); OS was tested at final analysis (FA; data cutoff, January 17, 2023). Efficacy boundaries were one-sided P = .0117 for PFS and OS. RESULTS: Four hundred ninety-two patients were randomly assigned to pembrolizumab plus chemotherapy (n = 245) or placebo plus chemotherapy (n = 247). At IA2, the median PFS was 5.6 months for pembrolizumab plus chemotherapy versus 5.5 months for placebo plus chemotherapy (hazard ratio [HR], 0.80 [95% CI, 0.65 to 0.97]; P = .0122). At FA, the median OS was 15.9 versus 14.7 months, respectively (HR, 0.84 [95% CI, 0.69 to 1.02]; P = .0362). Grade ≥3 treatment-related adverse events occurred in 43.7% of pembrolizumab plus chemotherapy recipients versus 38.6% of placebo plus chemotherapy recipients. CONCLUSION: Addition of pembrolizumab to chemotherapy in patients with TKI-resistant, EGFR-mutant, metastatic nonsquamous NSCLC did not significantly prolong PFS or OS versus placebo plus chemotherapy in KEYNOTE-789.

    DOI： 10.1200/JCO.23.02747

    PubMed

    researchmap

  • Primary prophylaxis with G-CSF for patients with non-round cell soft tissue sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology.

    Takeshi Hirose, Mamoru Ito, Kenji Tsuchihashi, Yukinori Ozaki, Hiroshi Nishio, Eiki Ichihara, Yuji Miura, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Makoto Endo

    International journal of clinical oncology   29 ( 8 )   1067 - 1073   2024年8月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: Granulocyte colony-stimulating factor (G-CSF) is an essential supportive agent for chemotherapy-induced severe myelosuppression. We proposed two clinical questions (CQ): CQ #1, "Does primary prophylaxis with G-CSF benefit chemotherapy for non-round cell soft tissue sarcoma (NRC-STS)?" and CQ #2, "Does G-CSF-based intensified chemotherapy improve NRC-STS treatment outcomes?" for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology. METHODS: A literature search was performed on the primary prophylactic use of G-CSF for NRC-STSs. Two reviewers assessed the extracted papers and analyzed overall survival, incidence of febrile neutropenia, infection-related mortality, quality of life, and pain. RESULTS: Eighty-one and 154 articles were extracted from the literature search for CQs #1 and #2, respectively. After the first and second screening, one and two articles were included in the final evaluation, respectively. Only some studies have addressed these two clinical questions through a literature review. CONCLUSION: The clinical questions were converted to future research questions because of insufficient available data. The statements were proposed: "The benefit of primary G-CSF prophylaxis is not clear in NRC-STS" and "The benefit of intensified chemotherapy with primary G-CSF prophylaxis is not clear in NRC-STSs." G-CSF is often administered as primary prophylaxis when chemotherapy with severe myelosuppression is administered. However, its effectiveness and safety are yet to be scientifically proven.

    DOI： 10.1007/s10147-024-02569-1

    PubMed

    researchmap

  • Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022.

    Kazuki Nozawa, Yukinori Ozaki, Tetsuhiro Yoshinami, Takamichi Yokoe, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano

    International journal of clinical oncology   29 ( 8 )   1074 - 1080   2024年8月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    INTRODUCTION: Chemotherapy for breast cancer can cause neutropenia, increasing the risk of febrile neutropenia (FN) and serious infections. The use of granulocyte colony-stimulating factors (G-CSF) as primary prophylaxis has been explored to mitigate these risks. To evaluate the efficacy and safety of primary G-CSF prophylaxis in patients with invasive breast cancer undergoing chemotherapy. METHODS: A systematic literature review was conducted according to the "Minds Handbook for Clinical Practice Guideline Development" using PubMed, Ichushi-Web, and the Cochrane Library databases. Randomized controlled trials (RCTs) and cohort studies assessing using G-CSF as primary prophylaxis in invasive breast cancer were included. The primary outcomes were overall survival (OS) and FN incidence. Meta-analyses were performed for outcomes with sufficient data. RESULTS: Eight RCTs were included in the qualitative analysis, and five RCTs were meta-analyzed for FN incidence. The meta-analysis showed a significant reduction in FN incidence with primary G-CSF prophylaxis (risk difference [RD] = 0.22, 95% CI: 0.01-0.43, p = 0.04). Evidence for improvement in OS with G-CSF was inconclusive. Four RCTs suggested a tendency for increased pain with G-CSF, but statistical significance was not reported. CONCLUSIONS: Primary prophylactic use of G-CSF is strongly recommended for breast cancer patients undergoing chemotherapy, as it has been shown to reduce the incidence of FN. While the impact on OS is unclear, the benefits of reducing FN are considered to outweigh the potential harm of increased pain.

    DOI： 10.1007/s10147-024-02570-8

    PubMed

    researchmap

  • Effectiveness and safety of primary prophylaxis with G-CSF for patients with Ewing sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology.

    Takeshi Hirose, Mamoru Ito, Kenji Tsuchihashi, Yukinori Ozaki, Hiroshi Nishio, Eiki Ichihara, Yuji Miura, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Makoto Endo

    International journal of clinical oncology   29 ( 8 )   1081 - 1087   2024年8月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: Multidrug chemotherapy for Ewing sarcoma can lead to severe myelosuppression. We proposed two clinical questions (CQ): CQ #1, "Does primary prophylaxis with G-CSF benefit chemotherapy for Ewing sarcoma?" and CQ #2, "Does G-CSF-based intensified chemotherapy improve Ewing sarcoma treatment outcomes?". METHODS: A comprehensive literature search was conducted in PubMed, Cochrane Library, and Ichushi web databases, including English and Japanese articles published from 1990 to 2019. Two reviewers assessed the extracted papers and analyzed overall survival (OS), febrile neutropenia (FN) incidence, infection-related mortality, quality of life (QOL), and pain. RESULTS: Twenty-five English and five Japanese articles were identified for CQ #1. After screening, a cohort study of vincristine, ifosfamide, doxorubicin, and etoposide chemotherapy with 851 patients was selected. Incidence of FN was 60.8% with G-CSF and 65.8% without; statistical tests were not conducted. Data on OS, infection-related mortality, QOL, or pain was unavailable. Consequently, CQ #1 was redefined as a future research question. As for CQ #2, we found two English and five Japanese papers, of which one high-quality randomized controlled trial on G-CSF use in intensified chemotherapy was included. This trial showed trends toward lower mortality and a significant increase in event-free survival for 2-week interval regimen with the G-CSF primary prophylactic use compared with 3-week interval. CONCLUSION: This review indicated that G-CSF's efficacy as primary prophylaxis in Ewing sarcoma, except in children, is uncertain despite its common use. This review tentatively endorses intensified chemotherapy with G-CSF primary prophylaxis for Ewing sarcoma.

    DOI： 10.1007/s10147-024-02572-6

    PubMed

    researchmap

  • Increased Oxidative Stress and Decreased Citrulline in Blood Associated with Severe Novel Coronavirus Pneumonia in Adult Patients. 国際誌

    Mitsuru Tsuge, Eiki Ichihara, Kou Hasegawa, Kenichiro Kudo, Yasushi Tanimoto, Kazuhiro Nouso, Naohiro Oda, Sho Mitsumune, Goro Kimura, Haruto Yamada, Ichiro Takata, Toshiharu Mitsuhashi, Akihiko Taniguchi, Kohei Tsukahara, Toshiyuki Aokage, Hideharu Hagiya, Shinichi Toyooka, Hirokazu Tsukahara, Yoshinobu Maeda

    International journal of molecular sciences   25 ( 15 )   2024年7月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    This study investigated the correlation between oxidative stress and blood amino acids associated with nitric oxide metabolism in adult patients with coronavirus disease (COVID-19) pneumonia. Clinical data and serum samples were prospectively collected from 100 adult patients hospitalized for COVID-19 between July 2020 and August 2021. Patients with COVID-19 were categorized into three groups for analysis based on lung infiltrates, oxygen inhalation upon admission, and the initiation of oxygen therapy after admission. Blood data, oxidative stress-related biomarkers, and serum amino acid levels upon admission were compared in these groups. Patients with lung infiltrations requiring oxygen therapy upon admission or starting oxygen post-admission exhibited higher serum levels of hydroperoxides and lower levels of citrulline compared to the control group. No remarkable differences were observed in nitrite/nitrate, asymmetric dimethylarginine, and arginine levels. Serum citrulline levels correlated significantly with serum lactate dehydrogenase and C-reactive protein levels. A significant negative correlation was found between serum levels of citrulline and hydroperoxides. Levels of hydroperoxides decreased, and citrulline levels increased during the recovery period compared to admission. Patients with COVID-19 with extensive pneumonia or poor oxygenation showed increased oxidative stress and reduced citrulline levels in the blood compared to those with fewer pulmonary complications. These findings suggest that combined oxidative stress and abnormal citrulline metabolism may play a role in the pathogenesis of COVID-19 pneumonia.

    DOI： 10.3390/ijms25158370

    PubMed

    researchmap

  • Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.

    Yuho Najima, Tomoya Maeda, Yutaro Kamiyama, Shinji Nakao, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miumra, Makoto Endo, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Shingo Yano

    International journal of clinical oncology   29 ( 7 )   899 - 910   2024年7月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: The outcomes of relapsed or refractory acute myeloid leukemia (AML) remain poor. Although the concomitant use of granulocyte colony-stimulating factor (G-CSF) and anti-chemotherapeutic agents has been investigated to improve the antileukemic effect on AML, its usefulness remains controversial. This study aimed to investigate the effects of G-CSF priming as a remission induction therapy or salvage chemotherapy. METHODS: We performed a thorough literature search for studies related to the priming effect of G-CSF using PubMed, Ichushi-Web, and the Cochrane Library. A qualitative analysis of the pooled data was performed, and risk ratios (RRs) with confidence intervals (CIs) were calculated and summarized. RESULTS: Two reviewers independently extracted and accessed the 278 records identified during the initial screening, and 62 full-text articles were assessed for eligibility in second screening. Eleven studies were included in the qualitative analysis and 10 in the meta-analysis. A systematic review revealed that priming with G-CSF did not correlate with an improvement in response rate and overall survival (OS). The result of the meta-analysis revealed the tendency for lower relapse rate in the G-CSF priming groups without inter-study heterogeneity [RR, 0.91 (95% CI 0.82-1.01), p = 0.08; I2 = 4%, p = 0.35]. In specific populations, including patients with intermediate cytogenetic risk and those receiving high-dose cytarabine, the G-CSF priming regimen prolonged OS. CONCLUSIONS: G-CSF priming in combination with intensive remission induction treatment is not universally effective in patients with AML. Further studies are required to identify the patient cohort for which G-CSF priming is recommended.

    DOI： 10.1007/s10147-023-02461-4

    PubMed

    researchmap

  • Pulmonary function and chest CT abnormalities 3 months after discharge from COVID-19, 2020-2021: A nation-wide multicenter prospective cohort study from the Japanese respiratory society. 国際誌

    Hirofumi Kamata, Kazufumi Takamatsu, Koichi Fukunaga, Shotaro Chubachi, Kensuke Nakagawara, Ho Namkoong, Hideki Terai, Katsushi Tanaka, Susumu Sato, Eri Hagiwara, Reoto Takei, Yasuhiro Kondoh, Takahiro Takazono, Midori Hashimoto, Sadatomo Tasaka, Takashi Ohrui, Yoshinori Tanino, Masamichi Mineshita, Yuko Komase, Kazuhito Miyazaki, Masanori Nishikawa, Akira Ando, Hideo Kita, Eiki Ichihara, Shinichiro Ohshimo, Yoriyuki Murata, Masayuki Ishida, Seiichi Kobayashi, Takahiro Uchida, Hiroki Tateno, Jun Ikari, Takeshi Terashima, Yutaka Kozu, Tomoya Tateishi, Masaharu Shinkai, Hironori Sagara, Yasuo To, Yoko Ito, Masaki Yamamoto, Yoshihiro Yamamoto, Toshiyuki Kita, Yutaka Ito, Keisuke Tomii, Yukio Fujita, Yoshihiro Funaki, Kazuhiro Yatera, Mari Yamasue, Kosaku Komiya, Satoko Kozawa, Hideaki Manabe, Hironao Hozumi, Tomoya Horiguchi, Takamasa Kitajima, Yasushi Nakano, Tetsutaro Nagaoka, Masayuki Hojo, Akinori Ebihara, Masayoshi Kobayashi, Koji Takayama, Torahiko Jinta, Toyomitsu Sawai, Yuichi Fukuda, Takeshi Kaneko, Kazuo Chin, Takashi Ogura, Hiroshi Mukae, Makoto Ishii, Akihito Yokoyama

    Respiratory investigation   62 ( 4 )   572 - 579   2024年7月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: No comprehensive analysis of the pulmonary sequelae of coronavirus disease 2019 (COVID-19) in Japan based on respiratory function tests and chest computed tomography (CT) has been reported. We evaluated post-COVID-19 conditions, especially focusing on pulmonary sequelae assessed by pulmonary function tests and chest CT. METHODS: For this prospective cohort study, we enrolled 1069 patients who presented pneumonia at the time of admission in 55 hospitals from February 2020 to September 2021. Disease severity was classified as moderateⅠ, moderate II, and severe, defined primarily according to the degree of respiratory failure. The data on post-COVID-19 conditions over 12 months, pulmonary function, and chest CT findings at 3 months were evaluated in this study. Additionally, the impact of COVID-19 severity on pulmonary sequelae, such as impaired diffusion capacity, restrictive pattern, and CT abnormalities, was also evaluated. RESULTS: The most frequently reported post-COVID-19 conditions at 3 months after COVID-19 were muscle weakness, dyspnea, and fatigue (48.4%, 29.0%, and 24.7%, respectively). The frequency of symptoms gradually decreased over subsequent months. In pulmonary function tests at 3 months, the incidence of impaired diffusion capacity and restrictive pattern increased depending on disease severity. There also were differences in the presence of chest CT abnormalities at the 3 months, which was markedly correlated with the severity. CONCLUSION: We reported a comprehensive analysis of post-COVID-19 condition, pulmonary function, and chest CT abnormalities in Japanese patients with COVID-19. The findings of this study will serve as valuable reference data for future post-COVID-19 condition research in Japan.

    DOI： 10.1016/j.resinv.2024.02.009

    PubMed

    researchmap

  • Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report. 国際誌

    Hiroaki Matsuura, Hisao Higo, Tadahiro Kuribayashi, Akihiko Tamaoki, Takamasa Nakasuka, Mari Uno, Go Makimoto, Kiichiro Ninomiya, Masanori Fujii, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Nobuaki Miyahara, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura, Kadoaki Ohashi

    Thoracic cancer   15 ( 17 )   1390 - 1394   2024年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    The concurrent incidence of lung cancer and tuberculosis is expected to escalate due to the projected growth in the older population. Combination therapy with osimertinib and antituberculosis drugs has not been well-established. We report a case of successful treatment involving the concomitant administration of osimertinib and antituberculosis drugs in an older patient, an 89-year-old female, diagnosed with epidermal growth factor receptor (EGFR)-mutant lung cancer and pulmonary tuberculosis. Accumulating evidence is warranted to develop an optimal treatment strategy for patients with lung cancer and tuberculosis.

    DOI： 10.1111/1759-7714.15324

    PubMed

    researchmap

  • Two Cases of Cytomegalovirus Colitis During the Treatment of Immune Checkpoint Inhibitor-Associated Colitis. 国際誌

    Masaya Iwamuro, Takehiro Tanaka, Go Makimoto, Eiki Ichihara, Sakiko Hiraoka

    Cureus   16 ( 6 )   e63308   2024年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Herein, we outlined two case reports of patients who developed cytomegalovirus colitis following the initiation of corticosteroid therapy for colitis as a result of immune-related adverse events (irAEs). For both patients, endoscopic findings were similar to those observed for patients with irAE colitis but were devoid of the characteristic features associated with cytomegalovirus colitis, including punched-out ulcers. Given the therapeutic disparities between these two conditions, it is imperative to distinguish between these conditions in clinical practice. When addressing exacerbations or refractory manifestations of irAE-associated colitis, clinicians should remain vigilant with regard to the potential for cytomegalovirus infection, even in the absence of punched-out ulcers in the colorectum.

    DOI： 10.7759/cureus.63308

    PubMed

    researchmap

  • Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.

    Kenji Tsuchihashi, Mamoru Ito, Yuta Okumura, Kenta Nio, Yukinori Ozaki, Hiroshi Nishio, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Eishi Baba

    International journal of clinical oncology   29 ( 6 )   700 - 705   2024年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: Febrile neutropenia represents a critical oncologic emergency, and its management is pivotal in cancer therapy. In several guidelines, the use of granulocyte colony-stimulating factor (G-CSF) in patients with chemotherapy-induced febrile neutropenia is not routinely recommended except in high-risk cases. The Japan Society of Clinical Oncology has updated its clinical practice guidelines for the use of G-CSF, incorporating a systematic review to address this clinical question. METHODS: The systematic review was conducted by performing a comprehensive literature search across PubMed, the Cochrane Library, and Ichushi-Web, focusing on publications from January 1990 to December 2019. Selected studies included randomized controlled trials (RCTs), non-RCTs, and cohort and case-control studies. Evaluated outcomes included overall survival, infection-related mortality, hospitalization duration, quality of life, and pain. RESULTS: The initial search yielded 332 records. Following two rounds of screening, two records were selected for both qualitative and quantitative synthesis including meta-analysis. Regarding infection-related mortality, the event to case ratio was 5:134 (3.73%) in the G-CSF group versus 6:129 (4.65%) in the non-G-CSF group, resulting in a relative risk of 0.83 (95% confidence interval, 0.27-2.58; p = 0.54), which was not statistically significant. Only median values for hospitalization duration were available from the two RCTs, precluding a meta-analysis. For overall survival, quality of life, and pain, no suitable studies were found for analysis, rendering their assessment unfeasible. CONCLUSION: A weak recommendation is made that G-CSF treatment not be administered to patients with febrile neutropenia during cancer chemotherapy. G-CSF treatment can be considered for patients at high risk.

    DOI： 10.1007/s10147-024-02541-z

    PubMed

    researchmap

  • Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology.

    Mamoru Ito, Yuta Okumura, Kenta Nio, Eishi Baba, Yukinori Ozaki, Hiroshi Nishio, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Kenji Tsuchihashi

    International journal of clinical oncology   29 ( 6 )   689 - 699   2024年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: Granulocyte colony-stimulating factor (G-CSF) reportedly reduces the risk of neutropenia and subsequent infections caused by cancer chemotherapy. Although several guidelines recommend using G-CSF in primary prophylaxis according to the incidence rate of chemotherapy-induced febrile neutropenia (FN), the effectiveness of G-CSF in digestive system tumor chemotherapy remains unclear. To address these clinical questions, we conducted a systematic review as part of revising the Clinical Practice Guidelines for the Use of G-CSF 2022 published by the Japan Society of Clinical Oncology. METHODS: This systematic review addressed two main clinical questions (CQ): CQ1: "Is primary prophylaxis with G-CSF effective in chemotherapy?", and CQ2: "Is increasing the intensity of chemotherapy with G-CSF effective?" We reviewed different types of digestive system tumors, including esophageal, gastric, pancreatic, biliary tract, colorectal, and neuroendocrine carcinomas. PubMed, Cochrane Library, and Ichushi-Web databases were searched for information sources. Independent systematic reviewers conducted two rounds of screening and selected relevant records for each CQ. Finally, the working group members synthesized the strength of evidence and recommendations. RESULTS: After two rounds of screening, 5/0/3/0/2/0 records were extracted for CQ1 of esophageal/gastric/pancreatic/biliary tract/colorectal/ and neuroendocrine carcinoma, respectively. Additionally, a total of 2/6/1 records were extracted for CQ2 of esophageal/pancreatic/colorectal cancer, respectively. The strength of evidence and recommendations were evaluated for CQ1 of colorectal cancer; however, we could not synthesize recommendations for other CQs owing to the lack of records. CONCLUSION: The use of G-CSF for primary prophylaxis in chemotherapy for colorectal cancer is inappropriate.

    DOI： 10.1007/s10147-024-02502-6

    PubMed

    researchmap

  • Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.

    Tetsuhiro Yoshinami, Kazuki Nozawa, Takamichi Yokoe, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano

    International journal of clinical oncology   29 ( 6 )   681 - 688   2024年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUD: Granulocyte colony-stimulating factor (G-CSF) is widely used for the primary prophylaxis of febrile neutropenia (FN). Two types of G-CSF are available in Japan, namely G-CSF chemically bound to polyethylene glycol (PEG G-CSF), which provides long-lasting effects with a single dose, and non-polyethylene glycol-bound G-CSF (non-PEG G-CSF), which must be sequentially administrated for several days. METHODS: This current study investigated the utility of these treatments for the primary prophylaxis of FN through a systematic review of the literature. A detailed literature search for related studies was performed using PubMed, Ichushi-Web, and the Cochrane Library. Data were independently extracted and assessed by two reviewers. A qualitative analysis or meta-analysis was conducted to evaluate six outcomes. RESULTS: Through the first and second screenings, 23 and 18 articles were extracted for qualitative synthesis and meta-analysis, respectively. The incidence of FN was significantly lower in the PEG G-CSF group than in the non-PEG G-CSF group with a strong quality/certainty of evidence. The differences in other outcomes, such as overall survival, infection-related mortality, the duration of neutropenia (less than 500/μL), quality of life, and pain, were not apparent. CONCLUSIONS: A single dose of PEG G-CSF is strongly recommended over multiple-dose non-PEG G-CSF therapy for the primary prophylaxis of FN.

    DOI： 10.1007/s10147-024-02504-4

    PubMed

    researchmap

  • Treatment rationale and protocol design: an investigator-initiated phase II study of combination treatment of nivolumab and TM5614, a PAI-1 inhibitor for previously treated patients with non-small cell lung cancer. 国際誌

    Takeshi Masuda, Taizo Hirata, Tomohiro Sakamoto, Yukari Tsubata, Eiki Ichihara, Toshiyuki Kozuki, Hiroyasu Shoda, Masanori Motonaga, Takako Yoshida, Miki Fukutani, Kazue Tsuji-Takayama, Atsushi Tamura, Harunobu Amagase, Hideki Fujihara, Gaku Aoki, Tomoyuki Akita, Yasushi Orihashi, Toshio Miyata, Noboru Hattori

    Journal of thoracic disease   16 ( 5 )   3381 - 3388   2024年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: There is no established standard 3rd line treatment for patients with advanced non-small cell lung cancer (NSCLC). Although cytotoxic chemotherapeutic agents that are not used as 1st or 2nd line treatment are administrated as 3rd line treatment, their anti-tumor efficacy is insufficient. Anti-programmed death ligand-1 (PD-L1)/programmed death-1 (PD1) treatment is more effective and less toxic than chemotherapy in anti-PD-L1/PD-1 treatment-naïve patients with NSCLC. Therefore, anti-PD-L1/PD-1 therapy is considered an appropriate 3rd line treatment. However, the anti-tumor efficacy is limited in patients previously treated with anti-PD-L1/PD-1 antibody. Today, new drugs are needed to increase the efficacy of anti-PD-L1/PD-1 antibodies. METHODS: This open-label, single-arm, investigator-initiated phase II study is designed to evaluate combination treatment of nivolumab and TM5614, a plasminogen activator inhibitor (PAI-1) inhibitor as 3rd or more line treatment in NSCLC patients who underwent standard treatment. The primary endpoint is the objective response rate and the secondary endpoints are progression-free survival (PFS), overall survival (OS), duration of response (DOR) and safety. Recruitment began in September 2023 and is expected to continue for approximately three years. DISCUSSION: Currently, there is no standard 3rd line treatment for advanced NSCLC, and we hope that the findings of this study will facilitate more effective treatments in this setting. Ethics and dissemination: the study protocol conformed to the ethical principles outlined in the Declaration of Helsinki. All patients will provide written informed consent prior to enrollment. Results will be published in a peer-reviewed publication. TRIAL REGISTRATION: This study is registered to Japan Registry of Clinical Trials with number: jRCT2061230039 (19/July/2023).

    DOI： 10.21037/jtd-23-1858

    PubMed

    researchmap

  • Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysiss. 国際誌

    David J H Bian, Anna-Maria Lazaratos, Sarah M Maritan, Andrea Quaiattini, Zhimin Zeng, Zhengfei Zhu, Ugur Sener, Rachna Malani, Yu Jung Kim, Eiki Ichihara, Victor Cohen, April A N Rose, Nathaniel Bouganim, Matthew Dankner

    Heliyon   10 ( 9 )   e29668   2024年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    PURPOSE: Leptomeningeal metastasis (LM) is a severe complication of non-small cell lung cancer (NSCLC). In patients with NSCLC LM harboring epidermal growth factor receptor (EGFR) mutations, osimertinib is favored over alternative EGFR tyrosine kinase inhibitors (TKIs). However, the efficacy of osimertinib relative to other EGFR-TKIs is not well established for patients with LM. We aimed to compare the efficacy of EGFR-TKIs in EGFR-mutated NSCLC LM. METHODS: This systematic review and meta-analysis performed according to PRISMA guidelines included studies of adult patients with EGFR-mutated NSCLC and a diagnosis of LM who received an EGFR-TKI for the treatment of LM. We searched Medline ALL, Embase, Cochrane Central Register of Controlled Trials, Scopus, and Web of Science Core Collection. The evaluation of biases was done by using the Ottawa-Newscastle scale. The hazard ratio was used as the parameter of interest for overall survival (OS) and central nervous system-specific progression-free survival (PFS). RESULTS: 128 publications were included with 243 patients and 282 lines of EGFR-TKI for NSCLC LM that met inclusion criteria. The median PFS in patients receiving any EGFR-TKI was 9.1 months, and the median OS was 14.5 months. In univariate analyses of the entire cohort, osimertinib treatment demonstrated significantly prolonged PFS, but not OS, compared to other EGFR-TKIs. Osimertinib demonstrated significantly prolonged PFS and OS in the subset of patients who were previously treated with EGFR-TKIs, but not in EGFR-TKI naïve patients. CONCLUSION: Osimertinib is associated with improved outcomes compared to other EGFR-TKIs, particularly in patients previously treated with EGFR-TKIs. An important limitation is that most patients were derived from retrospective reports. These results highlight the need for prospective studies for this difficult-to-treat patient population.

    DOI： 10.1016/j.heliyon.2024.e29668

    PubMed

    researchmap

  • Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer. 国際誌

    Ayako Morita, Eiki Ichihara, Koji Inoue, Keiichi Fujiwara, Toshihide Yokoyama, Daijiro Harada, Chihiro Ando, Hirohisa Kano, Naohiro Oda, Tomoki Tamura, Nobuaki Ochi, Haruyuki Kawai, Masaaki Inoue, Naofumi Hara, Nobukazu Fujimoto, Hirohisa Ichikawa, Isao Oze, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    International journal of cancer   154 ( 9 )   1607 - 1615   2024年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    The relationships between the therapeutic effects of immune checkpoint inhibitors (ICIs) and the intestinal flora have attracted increasing attention. However, the effects of oral probiotics on the efficacies of ICIs used to treat non-small-cell lung cancer (NSCLC) remain unclear. We investigated the effects of probiotics on the efficacies of ICIs in patients treated with and without chemotherapy. We investigated patients with advanced NSCLC on ICI monotherapy or combination ICI and chemotherapy using the Okayama Lung Cancer Study Group Immunotherapy Database (OLCSG-ID) and the Okayama Lung Cancer Study Group Immunochemotherapy Database (OLCSG-ICD). In total, 927 patients (482 on ICI monotherapy, 445 on an ICI + chemotherapy) were enrolled. Most were male, of good performance status, smokers, and without epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) mutations. Probiotics were administered to 19% of patients on ICI monotherapies and 17% of those on ICIs + chemotherapy. Of the former patients, progression-free survival (PFS) and overall survival (OS) were significantly better in the probiotics group (PFS 7.9 vs. 2.9 months, hazard ratio [HR] 0.54, p < .001; OS not attained vs. 13.1 months, HR 0.45, p < .001). Among patients receiving ICI and chemotherapy, there were no significant differences in PFS between those on probiotics and not but OS was significantly better in the probiotics group (PFS 8.8 vs. 8.6 months, HR 0.89, p = .43; OS not attained vs. 22.6 months, HR 0.61, p = .03). Patients on probiotics experienced better outcomes following ICI treatment.

    DOI： 10.1002/ijc.34842

    PubMed

    researchmap

  • 肝切除後の難治性気管支胆汁瘻に対してEndobronchial Watanabe Spigotの挿入が感染制御に有効であった1例

    宇野 真梨, 槇本 剛, 藤 智和, 大森 洋樹, 肥後 寿夫, 本倉 優美, 田中 孝明, 森 俊太, 大西 桐子, 二宮 貴一朗, 頼 冠名, 市原 英基, 田端 雅弘, 宮原 信明, 堀田 勝幸, 大橋 圭明

    気管支学   46 ( Suppl. )   S337 - S337   2024年5月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本呼吸器内視鏡学会  

    researchmap

  • Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology.

    Tomoya Maeda, Yuho Najima, Yutaro Kamiyama, Shinji Nakao, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miumra, Makoto Endo, Dai Maruyama, Tatsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Shingo Yano

    International journal of clinical oncology   29 ( 5 )   535 - 544   2024年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Although granulocyte colony-stimulating factor (G-CSF) reduces the incidence, duration, and severity of neutropenia, its prophylactic use for acute myeloid leukemia (AML) remains controversial due to a theoretically increased risk of relapse. The present study investigated the effects of G-CSF as primary prophylaxis for AML with remission induction therapy. A detailed literature search for related studies was performed using PubMed, Ichushi-Web, and the Cochrane Library. Data were independently extracted and assessed by two reviewers. A qualitative analysis of pooled data was conducted, and the risk ratio with corresponding confidence intervals was calculated in the meta-analysis and summarized. Sixteen studies were included in the qualitative analysis, nine of which were examined in the meta-analysis. Although G-CSF significantly shortened the duration of neutropenia, primary prophylaxis with G-CSF did not correlate with infection-related mortality. Moreover, primary prophylaxis with G-CSF did not affect disease progression/recurrence, overall survival, or adverse events, such as musculoskeletal pain. However, evidence to support or discourage the use of G-CSF as primary prophylaxis for adult AML patients with induction therapy remains limited. Therefore, the use of G-CSF as primary prophylaxis can be considered for adult AML patients with remission induction therapy who are at a high risk of infectious complications.

    DOI： 10.1007/s10147-023-02465-0

    PubMed

    researchmap

  • Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022.

    Keita Uchino, Shingo Tamura, Shoji Kimura, Keisuke Shigeta, Takahiro Kimura, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Yuji Miura

    International journal of clinical oncology   29 ( 5 )   545 - 550   2024年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Granulocyte colony-stimulating factor (G-CSF) decreases the incidence, duration, and severity of febrile neutropenia (FN); however, dose reduction or withdrawal is often preferred in the management of adverse events in the treatment of urothelial cancer. It is also important to maintain therapeutic intensity in order to control disease progression and thereby relieve symptoms, such as hematuria, infection, bleeding, and pain, as well as to prolong the survival. In this clinical question, we compared treatment with primary prophylactic administration of G-CSF to maintain therapeutic intensity with conventional standard therapy without G-CSF and examined the benefits and risks as major outcomes. A detailed literature search for relevant studies was performed using PubMed, Ichu-shi Web, and Cochrane Library. Data were extracted and evaluated independently by two reviewers. A qualitative analysis of the pooled data was performed, and the risk ratios with corresponding confidence intervals were calculated and summarized in a meta-analysis. Seven studies were included in the qualitative analysis, two of which were reviewed in the meta-analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) therapy, and one randomized controlled study showed a reduction in the incidence of FN. Primary prophylactic administration of G-CSF may be beneficial, as shown in a randomized controlled study of dose-dense MVAC therapy. However, there are no studies on other regimens, and we made a "weak recommendation to perform" with an annotation of the relevant regimen (dose-dense MVAC).

    DOI： 10.1007/s10147-024-02491-6

    PubMed

    researchmap

  • Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.

    Yukinori Ozaki, Takamichi Yokoe, Tetsuhiro Yoshinami, Kazuki Nozawa, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano

    International journal of clinical oncology   29 ( 5 )   551 - 558   2024年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    INTRODUCTION: The timing of prophylactic pegylated granulocyte colony-stimulating factor (G-CSF) administration during cancer chemotherapy varies, with Day 2 and Days 3-5 being the most common schedules. Optimal timing remains uncertain, affecting efficacy and adverse events. This systematic review sought to evaluate the available evidence on the timing of prophylactic pegylated G-CSF administration. METHODS: Based on the Minds Handbook for Clinical Practice Guideline Development, we searched the PubMed, Ichushi-Web, and Cochrane Library databases for literature published from January 1990 to December 2019. The inclusion criteria included studies among the adult population using pegfilgrastim. The search strategy focused on timing-related keywords. Two reviewers independently extracted and assessed the data. RESULTS: Among 300 initial search results, only four articles met the inclusion criteria. A meta-analysis for febrile neutropenia incidence suggested a potential higher incidence when pegylated G-CSF was administered on Days 3-5 than on Day 2 (odds ratio: 1.27, 95% CI 0.66-2.46, p = 0.47), with a moderate certainty of evidence. No significant difference in overall survival or mortality due to infections was observed. The trend of severe adverse events was lower on Days 3-5, without statistical significance (odds ratio: 0.72, 95% CI 0.14-3.67, p = 0.69) and with a moderate certainty of evidence. Data on pain were inconclusive. CONCLUSIONS: Both Day 2 and Days 3-5 were weakly recommended for pegylated G-CSF administration post-chemotherapy in patients with cancer. The limited evidence highlights the need for further research to refine recommendations.

    DOI： 10.1007/s10147-024-02499-y

    PubMed

    researchmap

  • Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022.

    Shoji Kimura, Keisuke Shigeta, Shingo Tamura, Keita Uchino, Takahiro Kimura, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Yuji Miura

    International journal of clinical oncology   29 ( 5 )   559 - 563   2024年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: Docetaxel (DTX) is commonly used as a primary chemotherapy, and cabazitaxel (CBZ) has shown efficacy in patients who are DTX resistant. Primary prophylactic granulocyte colony stimulating factor (G-CSF) therapy is currently used with CBZ treatment in routine clinical care in Japan. METHODS: In this study, we performed a systematic review following the Minds guidelines to investigate the effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for prostate cancer and to construct G-CSF guidelines for primary prophylaxis use during chemotherapy. A comprehensive literature search of various electronic databases (PubMed, Cochrane Library, and Ichushi) was performed on January 10, 2020, to identify studies published between January 1990 and December 31, 2019 that investigate the impact of primary prophylaxis with G-CSF during CBZ administration on clinical outcomes. RESULTS: Ultimately, nine articles were included in the qualitative systematic review. Primary G-CSF prophylaxis during CBZ administration for metastatic castration-resistant prostate cancer was difficult to assess in terms of correlation with overall survival, mortality from infection, and patients' quality of life. These difficulties were owing to the lack of randomized controlled trials comparing patients with and without primary prophylaxis of G-CSF during CBZ administration. However, some retrospective studies have suggested that it may reduce the incidence of febrile neutropenia. CONCLUSION: G-CSF may be beneficial as primary prophylaxis during CBZ administration for metastatic castration resistant prostate cancer, and we made a "weak recommendation to perform" with an annotation of the relevant regimen.

    DOI： 10.1007/s10147-024-02501-7

    PubMed

    researchmap

  • Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022

    Eiki Ichihara, Nobuaki Ochi, Go Makimoto, Kenichiro Kudo, Daijiro Harada, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Toshio Kubo

    International Journal of Clinical Oncology   29 ( 4 )   355 - 362   2024年2月

    　詳細を見る

    掲載種別：研究論文（学術雑誌）   出版者・発行元：Springer Science and Business Media LLC  

    DOI： 10.1007/s10147-024-02469-4

    researchmap

    その他リンク： https://link.springer.com/article/10.1007/s10147-024-02469-4/fulltext.html

  • Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005). 国際誌

    Nobuhiro Kanaji, Eiki Ichihara, Takaaki Tanaka, Takashi Ninomiya, Toshiyuki Kozuki, Nobuhisa Ishikawa, Kazuya Nishii, Hiroyasu Shoda, Kakuhiro Yamaguchi, Keita Kawakado, Yuko Toyoda, Masaaki Inoue, Nobuyuki Miyatake, Naoki Watanabe, Takuya Inoue, Hitoshi Mizoguchi, Yuta Komori, Kazuki Kojima, Norimitsu Kadowaki

    Lung   202 ( 1 )   63 - 72   2024年2月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    PURPOSE: This study investigated the safety and efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) re-administration after recovery from EGFR-TKI-induced interstitial lung disease (ILD). METHODS: This multicenter retrospective study collected data from consecutive advanced NSCLC patients who underwent EGFR-TKI re-administration after recovery from EGFR-TKI-induced ILD. RESULTS: Fifty-eight patients were registered. The grades of initial TKI-induced ILD were grade 1 to 4. TKIs used for re-administration were erlotinib for 15 patients, osimertinib for 15, gefitinib for 14, afatinib for 13 patients, and dacomitinib for 1 patient. ILD recurred in 13 patients (22.4%), comprising 3 patients with grade 1, 6 patients with grade 2, and 4 patients with grade 3. No significant associations were found between ILD recurrence and age, smoking history, performance status, time from initial ILD to TKI re-administration, or concomitant corticosteroid use. However, the incidence of ILD recurrence was high in cases of repeated use of gefitinib or erlotinib or first time use of osimertinib at TKI re-administration. The ILD recurrence rate was lowest in patients treated with first time use of gefitinib (8%) or erlotinib (8%), followed by patients treated with repeated use of osimertinib (9%). The response rate, median progression-free survival by TKI re-administration, and median overall survival were 55%, 9.6 and 84.8 months, respectively. CONCLUSION: This study showed that EGFR-TKI re-administration is a feasible and effective treatment for patients who recovered from EGFR-TKI-induced ILD. Our results indicate that re-administration of EGFR-TKI is an important option for long-term prognosis after recovery from EGFR-TKI-induced ILD.

    DOI： 10.1007/s00408-023-00669-9

    PubMed

    researchmap

  • Protracted coronavirus disease 2019 after chimeric antigen receptor-T cell therapy successfully treated with sequential multidrug therapy. 国際誌

    Masahiro Yamashita, Hisao Higo, Nobuharu Fujii, Chiaki Matsumoto, Go Makimoto, Kiichiro Ninomiya, Masanori Fujii, Kammei Rai, Eiki Ichihara, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Nobuaki Miyahara

    Respiratory medicine case reports   51   102104 - 102104   2024年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    A 56-year-old woman who received CD19 chimeric antigen receptor-T cell therapy for refractory diffuse large B-cell lymphoma developed severe coronavirus disease 2019 (COVID-19) and was treated with nirmatrelvir/ritonavir in April 2022. However, she experienced persistent fatigue and cough and fever in June. Computed tomography revealed bilateral ground-glass opacities (GGO), and the patient was treated with corticosteroids for organizing pneumonia after COVID-19. Partial improvement was observed, but new GGO appeared despite corticosteroid therapy. Genome analysis of severe acute respiratory syndrome coronavirus 2 detected Omicron variant BA.1.1.2, which was prevalent at the time of initial infection. The patient was diagnosed with protracted COVID-19 and was treated with remdesivir, molnupiravir, nirmatrelvir/ritonavir, and tixagevimab/cilgavimab. These treatments appeared to contribute to the improvement of protracted COVID-19.

    DOI： 10.1016/j.rmcr.2024.102104

    PubMed

    researchmap

  • Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L). 国際誌

    Yuichi Ozawa, Yasuhiro Koh, Tetsunari Hase, Kenji Chibana, Kyoichi Kaira, Kyoichi Okishio, Eiki Ichihara, Shuji Murakami, Mototsugu Shimokawa, Nobuyuki Yamamoto

    Therapeutic advances in medical oncology   16   17588359231225046 - 17588359231225046   2024年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: ALK-tyrosine kinase inhibitors (ALK-TKIs) are effective for treating non-small-cell lung cancer with ALK gene rearrangement; however, resistance is inevitable. Brigatinib is a unique ALK-TKI that is effective against many resistance mutations. However, data on factors associated with its efficacy and resistance mechanisms are limited. OBJECTIVES: This study will evaluate the efficacy and safety of brigatinib in the real world and explore factors related to its efficacy, safety, and resistance mechanisms. DESIGN: Prospective observational study. ETHICS: This study is approved by the Ethics Committee of Wakayama Medical University. Written informed consent will be obtained from all patients before study-related procedures. METHODS AND ANALYSIS: This study comprises three cohorts. Cohorts A, B, and 0 will enroll patients receiving alectinib as the first ALK-TKI, receiving alectinib as the first ALK-TKI and subsequently cytotoxic agents and/or lorlatinib after alectinib, and without a history of ALK-TKI, respectively. Overall, 100, 30, and 50 patients will be enrolled in Cohorts A, B, and 0, respectively. Circulating tumor DNA before starting brigatinib and at disease progression will be analyzed in all cohorts using a hypersensitive next-generation sequencing (NGS) PGDx Elio plasma resolve panel. Serum protein levels will be analyzed using the Milliplex xMAP assay system with a Luminex 200 (Luminex, Austin, USA). The enrollment period is 31 months and the patients will be observed for 2 years after enrollment. Archived tissues will be collected for NGS analysis, gene expression analysis, and immunohistochemistry staining 1 year after completion of registration. Quality of life and safety evaluation using electronic patient-reported outcomes will be investigated. DISCUSSION: This study will elucidate predictors of ALK-TKI efficacy and resistance mechanisms and evaluate the efficacy and safety of brigatinib in a real-world setting. The results will provide crucial information for establishing treatment strategies, discovering novel biomarkers, and developing new therapeutic agents. TRIAL REGISTRATION: UMIN000042439.

    DOI： 10.1177/17588359231225046

    PubMed

    researchmap

  • CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer. 国際誌

    Naofumi Hara, Eiki Ichihara, Hirohisa Kano, Chihiro Ando, Ayako Morita, Tatsuya Nishi, Sachi Okawa, Takamasa Nakasuka, Atsuko Hirabae, Masaya Abe, Noboru Asada, Kiichiro Ninomiya, Go Makimoto, Masanori Fujii, Toshio Kubo, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Translational lung cancer research   12 ( 10 )   2098 - 2112   2023年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: Epidermal growth factor receptor (EGFR) mutations, such as exon 19 deletion and exon 21 L858R, are driver oncogenes of non-small cell lung cancer (NSCLC), with EGFR tyrosine kinase inhibitors (TKIs) being effective against EGFR-mutant NSCLC. However, the efficacy of EGFR-TKIs is transient and eventually leads to acquired resistance. Herein, we focused on the significance of cell cycle factors as a mechanism to attenuate the effect of EGFR-TKIs in EGFR-mutant NSCLC before the emergence of acquired resistance. METHODS: Using several EGFR-mutant cell lines, we investigated the significance of cell cycle factors to attenuate the effect of EGFR-TKIs in EGFR-mutant NSCLC. RESULTS: In several EGFR-mutant cell lines, certain cancer cells continued to proliferate without EGFR signaling, and the cell cycle regulator retinoblastoma protein (RB) was not completely dephosphorylated. Further inhibition of phosphorylated RB with cyclin-dependent kinase (CDK) 4/6 inhibitors, combined with the EGFR-TKI osimertinib, enhanced G0/G1 cell cycle accumulation and growth inhibition of the EGFR-mutant NSCLC in both in vitro and in vivo models. Furthermore, residual RB phosphorylation without EGFR signaling was maintained by extracellular signal-regulated kinase (ERK) signaling, and the ERK inhibition pathway showed further RB dephosphorylation. CONCLUSIONS: Our study demonstrated that the CDK4/6-RB signal axis, maintained by the MAPK pathway, attenuates the efficacy of EGFR-TKIs in EGFR-mutant NSCLC, and targeting CDK4/6 enhances this efficacy. Thus, combining CDK4/6 inhibitors and EGFR-TKI could be a novel treatment strategy for TKI-naïve EGFR-mutant NSCLC.

    DOI： 10.21037/tlcr-23-99

    PubMed

    researchmap

  • 未治療Uncommon EGFR遺伝子変異陽性NSCLCへのアファチニブとプラチナ併用のランダム化第III相試験(ACHILLES/TORG1834)

    吉岡 弘鎮, 三浦 理, 三角 俊裕, 倉田 宝保, 時任 高章, 福原 達朗, 佐藤 悠城, 白石 祥理, 楠原 政一郎, 寺岡 俊輔, 加藤 晃史, 堀之内 秀仁, 滝口 裕一, 後藤 康洋, 田中 謙太郎, 金津 正樹, 池田 慧, 市原 英基, 田中 洋史, 岡本 浩明

    肺癌   63 ( 5 )   427 - 427   2023年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(NPO)日本肺癌学会  

    researchmap

  • Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer. 国際誌

    Chihiro Ando, Eiki Ichihara, Tatsuya Nishi, Ayako Morita, Naofumi Hara, Kenji Takada, Takamasa Nakasuka, Hiromi Watanabe, Hirohisa Kano, Kazuya Nishii, Go Makimoto, Takumi Kondo, Kiichiro Ninomiya, Masanori Fujii, Toshio Kubo, Kadoaki Ohashi, Ken-Ichi Matsuoka, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Cancer science   2023年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Gilteritinib is a multitarget tyrosine kinase inhibitor (TKI), approved for the treatment of FLT3-mutant acute myeloid leukemia, with a broad range of activity against several tyrosine kinases including anaplastic lymphoma kinase (ALK). This study investigated the efficacy of gilteritinib against ALK-rearranged non-small cell lung cancers (NSCLC). To this end, we assessed the effects of gilteritinib on cell proliferation, apoptosis, and acquired resistance responses in several ALK-rearranged NSCLC cell lines and mouse xenograft tumor models and compared its efficacy to alectinib, a standard ALK inhibitor. Gilteritinib was significantly more potent than alectinib, as it inhibited cell proliferation at a lower dose, with complete attenuation of growth observed in several ALK-rearranged NSCLC cell lines and no development of drug tolerance. Immunoblotting showed that gilteritinib strongly suppressed phosphorylated ALK and its downstream effectors, as well as mesenchymal-epithelial transition factor (MET) signaling. By comparison, MET signaling was enhanced in alectinib-treated cells. Furthermore, gilteritinib was found to more effectively abolish growth of ALK-rearranged NSCLC xenograft tumors, many of which completely receded. Interleukin-15 (IL-15) mRNA levels were elevated in gilteritinib-treated cells, together with a concomitant increase in the infiltration of tumors by natural killer (NK) cells, as assessed by immunohistochemistry. This suggests that IL-15 production along with NK cell infiltration may constitute components of the gilteritinib-mediated antitumor responses in ALK-rearranged NSCLCs. In conclusion, gilteritinib demonstrated significantly improved antitumor efficacy compared with alectinib against ALK-rearranged NSCLC cells, which can warrant its candidacy for use in anticancer regimens, after further examination in clinical trial settings.

    DOI： 10.1111/cas.15958

    PubMed

    researchmap

  • Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer: A Case Report.

    Takaaki Tanaka, Masataka Taoka, Go Makimoto, Kiichiro Ninomiya, Hisao Higo, Masanori Fujii, Eiki Ichihara, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda

    Internal medicine (Tokyo, Japan)   2023年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    A 55-year-old man with stage IV lung adenocarcinoma was treated with cisplatin, pemetrexed, nivolumab, and ipilimumab. Approximately 100 days after treatment initiation, he became disoriented and presented to the emergency department with a high fever. Blood tests revealed liver and kidney dysfunctions. Subsequently, the patient developed generalized convulsions that required intensive care. He was clinically diagnosed with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Organ damage was gradually controlled with immunosuppressive drugs, including steroids, and the patient was discharged. Successful treatment is rare in patients with CRS, including ICANS, during immune checkpoint inhibitor treatment for solid tumors.

    DOI： 10.2169/internalmedicine.2429-23

    PubMed

    researchmap

  • Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer. 国際誌

    Toshio Kubo, Eiki Ichihara, Daijiro Harada, Koji Inoue, Keiichi Fujiwara, Sinobu Hosokawa, Daizo Kishino, Haruyuki Kawai, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Respiratory investigation   61 ( 5 )   643 - 650   2023年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: Limited information on anticancer therapy for super-elderly patients with non-small-cell lung cancer is available. Immune checkpoint inhibitors offer long-term survival to elderly patients aged ≥65 years with non-small-cell lung cancer. However, the efficacy and safety of immune checkpoint inhibitors in more elderly patients are not well understood. METHODS: We retrospectively evaluated the efficacy and safety of immune checkpoint inhibitors in patients aged ≥85 years with advanced non-small-cell lung cancer at nine centers using the Okayama Lung Cancer Study Group-Immunotherapy Database. RESULTS: Among 531 patients who received immune checkpoint inhibitors, 16 were aged ≥85 years (median, 86.5 years; range, 85-93 years). Many had high programmed death-ligand 1 expression and received pembrolizumab as first-line therapy. The objective response rate, median progression-free survival, and median survival time were 25% (95% confidence interval: 1-49), 2.8 months (95% confidence interval: 1.7-4.5), and not reached (95% confidence interval: 4.7-not reached), respectively. Moreover, the 4-year overall survival rate was 60.8% (95% confidence interval: 29.3-81.7), and a long-lasting effect of immune checkpoint inhibitors was observed even in patients aged ≥85 years. The incidence of immune-related and grade ≥3 immune-related adverse events was 32% and 6%, respectively. CONCLUSIONS: The effect and toxicity of immune checkpoint inhibitors for patients aged ≥85 years were acceptable. Immune checkpoint inhibitors may be a treatment option for patients aged ≥85 years.

    DOI： 10.1016/j.resinv.2023.06.005

    PubMed

    researchmap

  • Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapies. 国際誌

    Naoya Kemmotsu, Kiichiro Ninomiya, Kei Kunimasa, Takamasa Ishino, Joji Nagasaki, Yoshihiro Otani, Hiroyuki Michiue, Eiki Ichihara, Kadoaki Ohashi, Takako Inoue, Motohiro Tamiya, Kazuko Sakai, Youki Ueda, Hiromichi Dansako, Kazuto Nishio, Katsuyuki Kiura, Isao Date, Yosuke Togashi

    International journal of cancer   2023年8月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Intracranial metastases are common in nonsmall-cell lung cancer (NSCLC) patients, whose prognosis is very poor. In addition, intracranial progression is common during systemic treatments due to the inability to penetrate central nervous system (CNS) barriers, whereas the intracranial effects of cancer immunotherapies remain unclear. We analyzed clinical data to evaluate the frequency of intracranial progression in advanced NSCLC patients treated with PD-1 blockade therapies compared with those treated without PD-1 blockade therapies, and found that the frequency of intracranial progression in advanced NSCLC patients treated with PD-1 blockade therapies was significantly lower than that in patients treated with cytotoxic chemotherapies. In murine models, intracranial rechallenged tumors after initial rejection by PD-1 blockade were suppressed. Accordingly, long-lived memory precursor effector T cells and antigen-specific T cells were increased by PD-1 blockade in intracranial lesions. However, intracranial rechallenged different tumors are not suppressed. Our results indicate that cancer immunotherapies can prevent intracranial progression, maintaining long-term effects intracranially as well as systemically. If intracranial recurrence occurs during the treatment with PD-1 blockade therapies, aggressive local therapies could be worthwhile.

    DOI： 10.1002/ijc.34700

    PubMed

    researchmap

  • PD-1 blockade augments CD8+ T cell dependent antitumor immunity triggered by Ad-SGE-REIC in Egfr-mutant lung cancer. 国際誌

    Takamasa Nakasuka, Kadoaki Ohashi, Kazuya Nishii, Atsuko Hirabae, Sachi Okawa, Nahoko Tomonobu, Kenji Takada, Chihiro Ando, Hiromi Watanabe, Go Makimoto, Kiichiro Ninomiya, Masanori Fujii, Toshio Kubo, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Hiromi Kumon, Yoshinobu Maeda, Katsuyuki Kiura

    Lung cancer (Amsterdam, Netherlands)   178   1 - 10   2023年2月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    OBJECTIVES: No immunotherapeutic protocol has yet been established in never-smoking patients with lung cancer harboring driver oncogenic mutations, such as epidermal growth factor receptor (EGFR) mutations. The immunostimulatory effect of Ad-REIC, a genetically engineered adenovirus vector expressing a tumor suppressor gene, reduced expression in immortalized cells (REIC), has been investigated in clinical trials for various solid tumors. However, the immunostimulatory effect of the Ad-REIC in EGFR-mutant lung cancer with a non-inflamed tumor microenvironment (TME) has not been explored. MATERIALS AND METHODS: We used a syngeneic mouse model developed by transplanting Egfr-mutant lung cancer cells into single or double flanks of C57BL/6J mice. Ad-SGE-REIC, a 2nd-generation vector with an enhancer sequence, was injected only into the tumors from one flank, and its antitumor effects were assessed. Tumor-infiltrating cells were evaluated using immunohistochemistry or flow cytometry. The synergistic effects of Ad-SGE-REIC and PD-1 blockade were also examined. RESULTS: Injection of Ad-SGE-REIC into one side of the tumor induced not only a local antitumor effect but also a bystander abscopal effect in the non-injected tumor, located on the other flank. The number of PD-1+CD8+ T cells increased in both injected and non-injected tumors. PD-1 blockade augmented the local and abscopal antitumor effects of Ad-SGE-REIC by increasing the number of CD8+ T cells in the TME of Egfr-mutant tumors. Depletion of CD8+ cells reverted the antitumor effect, suggesting they contribute to antitumor immunity. CONCLUSION: Ad-SGE-REIC induced systemic antitumor immunity by modifying the TME status from non-inflamed to inflamed, with infiltration of CD8+ T cells. Additionally, in Egfr-mutant lung cancer, this effect was enhanced by PD-1 blockade. These findings pave the way to establish a novel combined immunotherapy strategy with Ad-SGE-REIC and anti-PD-1 antibody for lung cancer with a non-inflamed TME.

    DOI： 10.1016/j.lungcan.2023.01.018

    PubMed

    researchmap

  • A randomized controlled trial of teprenone in terms of preventing worsening of COVID-19 infection. 国際誌

    Eiki Ichihara, Kou Hasegawa, Kenichiro Kudo, Yasushi Tanimoto, Kazuhiro Nouso, Naohiro Oda, Sho Mitsumune, Haruto Yamada, Ichiro Takata, Hideharu Hagiya, Toshiharu Mitsuhashi, Akihiko Taniguchi, Shinichi Toyooka, Kohei Tsukahara, Toshiyuki Aokage, Hirokazu Tsukahara, Katsuyuki Kiura, Yoshinobu Maeda

    PloS one   18 ( 10 )   e0287501   2023年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: Some COVID-19 patients develop life-threatening disease accompanied by severe pneumonitis. Teprenone induces expression of heat-shock proteins (HSPs) that protect against interstitial pneumonia in preclinical models. We explored whether teprenone prevented worsening of COVID-19 infections. METHODS: This open-label, randomized, pilot phase 2 clinical trial was conducted at five institutions in Japan. We randomized patients hospitalized for COVID-19 with fever to teprenone or no-teprenone groups in a 1:1 ratio. We stratified patients by sex, age < and ≥ 70 years and the existence (or not) of complications (hypertension, diabetes, ischemic heart disease, chronic pulmonary disease and active cancer). No limitation was imposed on other COVID-19 treatments. The primary endpoint was the intubation rate. RESULTS: One hundred patients were included, 51 in the teprenone and 49 in the no- teprenone groups. The intubation rate did not differ significantly between the two groups: 9.8% (5/51) vs. 2.0% (1/49) (sub-hazard ratio [SHR] 4.99, 95% confidence interval [CI]: 0.59-42.1; p = 0.140). The rates of intra-hospital mortality and intensive care unit (ICU) admission did not differ significantly between the two groups: intra-hospital mortality 3.9% (2/51) vs. 4.1% (2/49) (hazard ratio [HR] 0.78, 95%CI: 0.11-5.62; p = 0.809); ICU admission 11.8% (6/51) vs. 6.1% (3/49) (SHR 1.99, 95%CI: 0.51-7.80; p = 0.325). CONCLUSION: Teprenone afforded no clinical benefit. TRIAL REGISTRATION: Japan Registry of Clinical Trials jRCTs061200002 (registered on 20/May/2020).

    DOI： 10.1371/journal.pone.0287501

    PubMed

    researchmap

  • The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study. 国際誌

    Tomoka Nishimura, Eiki Ichihara, Toshihide Yokoyama, Koji Inoue, Tomoki Tamura, Ken Sato, Naohiro Oda, Hirohisa Kano, Daizo Kishino, Haruyuki Kawai, Masaaki Inoue, Nobuaki Ochi, Nobukazu Fujimoto, Hirohisa Ichikawa, Chihiro Ando, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    Cancers   14 ( 24 )   2022年12月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Objectives: Combined immune checkpoint inhibitor (ICI) therapy and chemotherapy has become the standard treatment for advanced non-small-cell lung cancer (NSCLC). Pleural effusion (PE) is associated with poor outcomes among patients with NSCLC undergoing chemotherapy. However, minimal data exists on PE for patients undergoing combined ICI and chemotherapy. Therefore, we investigated how PE affects survival outcomes in patients with NSCLC undergoing this combined therapy. Methods: We identified patients with advanced NSCLC undergoing chemotherapy and ICI therapy from the Okayama Lung Cancer Study Group−Immune Chemotherapy Database (OLCSG−ICD) between December 2018 and December 2020; the OLCSG−ICD includes the clinical data of patients with advanced NSCLC from 13 institutions. Then, we analyzed the treatment outcomes based on the presence of PE. Results: We identified 478 patients who underwent combined ICI therapy and chemotherapy; 357 patients did not have PE, and 121 patients did have PE. Patients with PE had significantly shorter progression-free survival (PFS) and overall survival (OS) than those without PE (median PFS: 6.2 months versus 9.1 months; p < 0.001; median OS: 16.4 months versus 27.7 months; p < 0.001). The negative effect of PE differed based on the patient’s programmed cell death-ligand 1 (PD-L1) expression status; with the effect being more evident in patients with high PD-L1 expression. In addition, PFS and OS did not differ between patients who did and did not undergo bevacizumab treatment; thus, bevacizumab-containing regimens did not improve the survival outcomes for patients with PE. Conclusion: PE is associated with poor outcomes among patients with NSCLC undergoing combined ICI therapy and chemotherapy.

    DOI： 10.3390/cancers14246184

    PubMed

    researchmap

  • More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance. 国際誌

    Chihiro Ando, Eiki Ichihara, Toshihide Yokoyama, Koji Inoue, Tomoki Tamura, Keiichi Fujiwara, Naohiro Oda, Hirohisa Kano, Daizo Kishino, Kazuhiko Watanabe, Masaaki Inoue, Nobuaki Ochi, Fumie Onishi, Hirohisa Ichikawa, Hiroshi Kobe, Sayaka Tachibana, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    Journal of cancer research and clinical oncology   2022年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: Combination therapy with immune checkpoint inhibitors (ICIs) and chemotherapy (ICI + chemotherapy) has become the standard first line treatment for driver oncogene-negative advanced non-small-cell lung cancer (NSCLC). However, it may be more toxic compared to monotherapy, which limits its use. Moreover, the feasibility of the combination therapy in clinical practice remains unknown. METHODS: We conducted a cohort study to determine the implementation rate of ICI + chemotherapy in clinical practice. We retrospectively reviewed clinical data from advanced NSCLC patients who received systemic therapy at 13 institutions between December 2018 and December 2020. RESULTS: After excluding 154 patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) gene alterations, a total of 919 NSCLC patients were included. Among them, 442 were treated with ICI + chemotherapy (48%), whereas 477 were treated with other therapies (52%). Among these 477 patients, 340 did not receive ICI + chemotherapy because of intolerance (71%); thus, more than one-third of the advanced NSCLC patients do not benefit from the combination therapy due to intolerance. Among the 659 NSCLC patients for whom PD-L1 was < 50% or unknown, only 342 received the ICI + chemotherapy combination (52%) even though it is considered preferable to either therapy alone; the remaining 318 patients were treated with other therapies (48%). Among the 318 patients who did not receive ICI + chemotherapy, 274 were intolerant to it (86%). CONCLUSION: Our results revealed that a substantial proportion of advanced NSCLC patients did not benefit from ICI + chemotherapy due to intolerance. As treatments for NSCLC are moving toward combinations for greater efficacy, their feasibility in clinical practice must be taken into consideration.

    DOI： 10.1007/s00432-022-04415-1

    PubMed

    researchmap

  • COVID-19 Vaccine-Associated Lymphadenopathy Mimicking Regrowth of Axillary Lymph Node Metastasis of Lung Adenocarcinoma.

    Taku Noumi, Hiromi Watanabe, Kiichiro Ninomiya, Kadoaki Ohashi, Eiki Ichihara, Toshio Kubo, Go Makimoto, Yuka Kato, Masanori Fujii, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Hotta, Katsuyuki Kiura

    Acta medica Okayama   76 ( 5 )   593 - 596   2022年10月

    　詳細を見る

    記述言語：英語  

    We encountered a woman with re-enlarged axillary lymph nodes during a computed tomography (CT) scan for surveillance of lung adenocarcinoma with axillary lymph node metastasis at the initial diagnosis that had shrunk with standard chemotherapy. We first suspected cancer recurrence and considered a change in the chemotherapeutic regimen. However, after careful history taking regarding the timing of her Coronavirus Disease 2019 (COVID-19) vaccination, and subsequent careful, close follow-up, radiological shrinkage suggested a strictly benign cause. Especially in lung cancer with a medical history of axillary lymph node involvement, cliniciansshould be aware that vaccine-associated lymphadenopathy can mimic cancer recurrence and sometimesprompt serious misjudgment regarding a current treatment course and strategy.

    DOI： 10.18926/AMO/64041

    PubMed

    researchmap

  • 切除不能進行/転移・再発固形癌に対するePROモニタリングの有用性を検証する比較試験

    平 成人, 南 博信, 岩田 広治, 弦間 昭彦, 室 圭, 市原 英基, 加藤 恭子, 木川 雄一郎, 清田 尚臣, 久保田 馨, 建石 良介, 中田 晃暢, 中村 圭一郎, 成田 有季哉, 堀田 勝幸

    日本癌治療学会学術集会抄録集   60回   O48 - 3   2022年10月

    　詳細を見る

    記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

    researchmap

  • A Case of Anti-SOX1 Antibody-positive Small-cell Lung Cancer that Triggered Opsoclonus.

    Yuki Chiko, Yuka Sugisaki, Keiji Miyoshi, Daisuke Morichika, Yuka Beika, Akihiko Taniguchi, Eiki Ichihara, Toshiaki Okada

    Internal medicine (Tokyo, Japan)   2022年8月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    A 72-year-old woman with opsoclonus visited our hospital and was diagnosed with small-cell lung cancer. Blood tests revealed anti-SOX1 antibodies, so the patient was diagnosed with paraneoplastic opsoclonus-myoclonus syndrome. After steroid pulse therapy was started, chemotherapy of treatment, the opsoclonus showed an improving trend. Anti-Ri and anti-Hu antibodies have been reported as autoantibodies associated with neoplastic opsoclonus-myoclonus syndrome; however, there are no such reports concerning anti-SOX1 antibody. Therefore, this is a valuable case.

    DOI： 10.2169/internalmedicine.0168-22

    PubMed

    researchmap

  • Mixed response to cancer immunotherapy is driven by intratumor heterogeneity and differential inter-lesion immune infiltration

    Takao Morinaga, Takashi Inozume, Masahito Kawazu, Youki Ueda, Nicolas Sax, Kazuo Yamashita, Shusuke Kawashima, Joji Nagasaki, Toshihide Ueno, Jason Lin, Yuuki Ohara, Takeshi Kuwata, Hiroki Yukami, Akihito Kawazoe, Kohei Shitara, Akiko Honobe-Tabuchi, Takehiro Ohnuma, Tatsuyoshi Kawamura, Yoshiyasu Umeda, Yu Kawahara, Yasuhiro Nakamura, Yukiko Kiniwa, Ayako Morita, Eiki Ichihara, Katsuyuki Kiura, Tomohiro Enokida, Makoto Tahara, Yoshinori Hasegawa, Hiroyuki Mano, Yutaka Suzuki, Hiroyoshi Nishikawa, Yosuke Togashi

    Cancer Research Communications   2 ( 7 )   739 - 753   2022年7月

    　詳細を見る

    掲載種別：研究論文（学術雑誌）   出版者・発行元：American Association for Cancer Research (AACR)  

    Abstract

    Some patients experience mixed response to immunotherapy, whose biological mechanisms and clinical impact have been obscure. We obtained two tumor samples from lymph node (LN) metastatic lesions in a same patient. Whole exome sequencing for the both tumors and single-cell sequencing for the both tumor-infiltrating lymphocytes (TILs) demonstrated a significant difference in tumor clonality and TILs’ characteristics, especially exhausted T cell clonotypes, although a close relationship between the tumor cell and T cell clones were observed as a response of an overlapped exhausted T cell clone to an overlapped neoantigen. To mimic the clinical setting, we generated a mouse model of several clones from a same tumor cell line. Similarly, differential tumor clones harbored distinct TILs, and one responded to PD-1 blockade but the other did not in this model. We further conducted cohort study (n = 503) treated with PD-1 blockade monotherapies to investigate the outcome of mixed response. Patients with mixed responses to PD-1 blockade had a poor prognosis in our cohort. Particularly, there were significant differences in both tumor and T cell clones between the primary and LN lesions in a patient who experienced tumor response to anti-PD-1 mAb followed by disease progression in only LN metastasis. Our results underscore that intertumoral heterogeneity alters characteristics of TILs even in the same patient, leading to mixed response to immunotherapy and significant difference in the outcome.

    DOI： 10.1158/2767-9764.crc-22-0050

    researchmap

  • CD8+ T-cell responses are boosted by dual PD-1/VEGFR2 blockade after EGFR inhibition in Egfr-mutant lung cancer. 国際誌

    Kazuya Nishii, Kadoaki Ohashi, Shuta Tomida, Takamasa Nakasuka, Atsuko Hirabae, Sachi Okawa, Jun Nishimura, Hisao Higo, Hiromi Watanabe, Hirohisa Kano, Chihiro Ando, Go Makimoto, Kiichiro Ninomiya, Yuka Kato, Toshio Kubo, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Shinichi Toyooka, Heiichiro Udono, Yoshinobu Maeda, Katsuyuki Kiura

    Cancer immunology research   10 ( 9 )   1111 - 1126   2022年7月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Epidermal growth factor receptor (EGFR) is the most frequently mutated driver oncogene in non-smoking-related, non-small-cell lung cancer (NSCLC). EGFR-mutant NSCLC has a non-inflamed tumor microenvironment (TME), with low infiltration by CD8+ T cells and, thus, immune checkpoint inhibitors, such as anti-programmed cell death-1 (anti-PD-1) have weak anti-tumor effects. Here, we showed that CD8+ T-cell responses were induced by an EGFR-tyrosine kinase inhibitor (TKI) in syngeneic Egfr-mutant NSCLC tumors, which was further pronounced by sequential dual blockade of PD-1 and vascular endothelial growth factor receptor 2 (VEGFR2). However, simultaneous triple blockade had no such effect. PD-1/VEGFR2 dual blockade did not exert tumor-inhibitory effects without pre-treatment with the EGFR-TKI, suggesting that treatment schedule is crucial for efficacy of the dual blockade therapy. Pre-treatment with EGFR-TKI increased the CD8+ T-cell/regulatory T-cell (Treg) ratio, while also increasing expression of immunosuppressive chemokines and chemokine receptors, as well as increasing the number of M2-like macrophages, in the TME. Discontinuing EGFR-TKI treatment reversed the transient increase of immunosuppressive factors in the TME. The subsequent PD-1/VEGFR2 inhibition maintained increased numbers of infiltrating CD8+ T cells and CD11c+ dendritic cells. Depletion of CD8+ T cells in vivo abolished tumor growth inhibition by EGFR-TKI alone and the sequential triple therapy, suggesting that EGFR inhibition is a prerequisite for the induction of CD8+ T-cell responses. Our findings could aid in developing an alternative immunotherapy strategy in patients with cancers that have driver mutations and a non-inflamed TME.

    DOI： 10.1158/2326-6066.CIR-21-0751

    PubMed

    researchmap

  • Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801.

    Shinobu Hosokawa, Eiki Ichihara, Daijiro Harada, Shoichi Kuyama, Koji Inoue, Kenichi Gemba, Hirohisa Ichikawa, Yuka Kato, Naohiro Oda, Isao Oze, Tomoki Tamura, Toshiyuki Kozuki, Takahiro Umeno, Toshio Kubo, Katsuyuki Hotta, Akihiro Bessho, Yoshinobu Maeda, Katsuyuki Kiura

    International journal of clinical oncology   27 ( 7 )   1139 - 1144   2022年7月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: The role of pembrolizumab in the treatment of poor performance status (PS) patients remains unclear. PATIENTS AND METHODS: We conducted a phase II trial to investigate the efficacy and safety of pembrolizumab as first-line therapy for non-small-cell lung cancer (NSCLC) patients with PSs of 2-3 and programmed cell death ligand 1 (PD-L1) expression ≥ 50%. The primary endpoint of this study was the objective response rate (ORR). RESULTS: Fourteen patients treated at eight institutions were enrolled. Most patients had PS 2 (12/14; 86%) and others had PS 3 (2/14; 14%). The ORR was 57.1% (95% confidence interval 28.9-82.3%), which met the primary endpoint. The median progression-free survival (PFS) and 1-year PFS rates were 5.8 months and 20.0%, respectively. At the time of data cut-off, one patient had received treatment for more than 1 year; another patient had received treatment for more than 2 years. Nine patients had improved PS with treatment (Wilcoxon signed-rank test, p = 0.003). Two patients had immune-related adverse events ≥ grade 3: grades 5 and 3 elevation in alanine and aspartate aminotransferases. Two PS 3-stage patients were diagnosed with clinically progressive disease prior to initial computed tomography; both died within 2 months. CONCLUSION: Pembrolizumab was effective for the treatment of NSCLC patients with a poor PS and PD-L1 level ≥ 50%. However, given the poor outcomes of the PS 3 patients, the drug is not indicated for such patients. Adverse events, including liver dysfunction, should be carefully monitored. REGISTRATION ID: UMIN000030955.

    DOI： 10.1007/s10147-022-02164-2

    PubMed

    researchmap

  • Three doses of mRNA COVID‐19 vaccine protects from SARS‐CoV‐2 infections in Japan 国際誌

    Katsuyuki Hotta, Etsuji Suzuki, Eiki Ichihara, Katsuyuki Kiura

    Journal of Internal Medicine   292 ( 4 )   687 - 689   2022年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

    DOI： 10.1111/joim.13526

    PubMed

    researchmap

    その他リンク： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/joim.13526

  • がん遺伝子パネル検査を行った胸腺がん5例の検討

    久保 寿夫, 二宮 貴一朗, 槇本 剛, 加藤 有加, 藤井 昌学, 市原 英基, 大橋 圭明, 堀田 勝幸, 田端 雅弘, 前田 嘉信, 木浦 勝行

    日本呼吸器学会誌   11 ( 増刊 )   279 - 279   2022年4月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本呼吸器学会  

    researchmap

  • Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B).

    Yukari Tsubata, Kana Watanabe, Ryota Saito, Atsushi Nakamura, Hiroshige Yoshioka, Mami Morita, Ryoichi Honda, Nobuhiro Kanaji, Satoshi Oizumi, Daisuke Jingu, Taku Nakagawa, Kensuke Nakazawa, Atsuto Mouri, Susumu Takeuchi, Naoki Furuya, Yuki Akazawa, Kiyotaka Miura, Eiki Ichihara, Makoto Maemondo, Satoshi Morita, Kunihiko Kobayashi, Takeshi Isobe

    International journal of clinical oncology   27 ( 4 )   823 - 824   2022年4月

    　詳細を見る

  • Nintedanib plus chemotherapy for non-small cell lung cancer with IPF: a randomized phase 3 trial. 国際誌

    Kohei Otsubo, Junji Kishimoto, Masahiko Ando, Hirotsugu Kenmotsu, Yuji Minegishi, Hidehito Horinouchi, Terufumi Kato, Eiki Ichihara, Masashi Kondo, Shinji Atagi, Motohiro Tamiya, Satoshi Ikeda, Toshiyuki Harada, Shinnosuke Takemoto, Hidetoshi Hayashi, Keita Nakatomi, Yuichiro Kimura, Yasuhiro Kondoh, Masahiko Kusumoto, Kazuya Ichikado, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Yoichi Nakanishi, Isamu Okamoto

    The European respiratory journal   60 ( 6 )   2022年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease implicated as an independent risk factor for lung cancer. However, optimal treatment for advanced lung cancer with IPF remains to be established. We performed a randomised phase 3 trial to assess the efficacy and safety of nintedanib plus chemotherapy (experimental arm) compared with chemotherapy alone (standard-of-care arm) for advanced non-small cell lung cancer (NSCLC) with IPF. METHODS: Chemotherapy-naïve advanced NSCLC patients with IPF were allocated to receive carboplatin (area under the curve of 6 on day 1) plus nab-paclitaxel (100 mg m-2 on days 1, 8, and 15) every 3 weeks with or without nintedanib (150 mg b.i.d., daily). The primary end point was exacerbation-free survival (EFS). RESULTS: Between May 2017 and February 2020, 243 patients were enrolled. Median EFS was 14.6 months in the nintedanib plus chemotherapy group and 11.8 months in the chemotherapy group (HR, 0.89; 90% CI, 0.67-1.17; p=0.24), whereas median progression-free survival was 6.2 and 5.5 months, respectively (HR, 0.68; 95% CI, 0.50-0.92). Overall survival was improved by nintedanib in patients with nonsquamous histology (HR, 0.61; 95% CI, 0.40-0.93) and in those at GAP stage I (HR, 0.61; 95% CI, 0.38-0.98). Seven (2.9%) of 240 patients experienced acute exacerbation during study treatment. CONCLUSIONS: The primary end point of the study was not met. However, carboplatin plus nab-paclitaxel was found to be effective and tolerable in advanced NSCLC patients with IPF. Moreover, nintedanib in combination with such chemotherapy improved overall survival in patients with nonsquamous histology.

    DOI： 10.1183/13993003.00380-2022

    PubMed

    researchmap

  • Identification of targetable kinases in idiopathic pulmonary fibrosis. 国際誌

    Hisao Higo, Kadoaki Ohashi, Shuta Tomida, Sachi Okawa, Hiromasa Yamamoto, Seiichiro Sugimoto, Satoru Senoo, Go Makimoto, Kiichiro Ninomiya, Takamasa Nakasuka, Kazuya Nishii, Akihiko Taniguchi, Toshio Kubo, Eiki Ichihara, Katsuyuki Hotta, Nobuaki Miyahara, Yoshinobu Maeda, Shinichi Toyooka, Katsuyuki Kiura

    Respiratory research   23 ( 1 )   20 - 20   2022年2月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: Tyrosine kinase activation plays an important role in the progression of pulmonary fibrosis. In this study, we analyzed the expression of 612 kinase-coding and cancer-related genes using next-generation sequencing to identify potential therapeutic targets for idiopathic pulmonary fibrosis (IPF). METHODS: Thirteen samples from five patients with IPF (Cases 1-5) and eight samples from four patients without IPF (control) were included in this study. Six of the thirteen samples were obtained from different lung segments of a single patient who underwent bilateral pneumonectomy. Gene expression analysis of IPF lung tissue samples (n = 13) and control samples (n = 8) was performed using SureSelect RNA Human Kinome Kit. The expression of the selected genes was further confirmed at the protein level by immunohistochemistry (IHC). RESULTS: Gene expression analysis revealed a correlation between the gene expression signatures and the degree of fibrosis, as assessed by Ashcroft score. In addition, the expression analysis indicated a stronger heterogeneity among the IPF lung samples than among the control lung samples. In the integrated analysis of the 21 samples, DCLK1 and STK33 were found to be upregulated in IPF lung samples compared to control lung samples. However, the top most upregulated genes were distinct in individual cases. DCLK1, PDK4, and ERBB4 were upregulated in IPF case 1, whereas STK33, PIM2, and SYK were upregulated in IPF case 2. IHC revealed that these proteins were expressed in the epithelial layer of the fibrotic lesions. CONCLUSIONS: We performed a comprehensive kinase expression analysis to explore the potential therapeutic targets for IPF. We found that DCLK1 and STK33 may serve as potential candidate targets for molecular targeted therapy of IPF. In addition, PDK4, ERBB4, PIM2, and SYK might also serve as personalized therapeutic targets of IPF. Additional large-scale studies are warranted to develop personalized therapies for patients with IPF.

    DOI： 10.1186/s12931-022-01940-y

    PubMed

    researchmap

  • Massive hemoptysis in a post-operative patient with recurrent lung cancer successfully treated by the combination therapy of Endobronchial Watanabe Spigot and bronchial artery embolization. 国際誌

    Masataka Taoka, Go Makimoto, Noriyuki Umakoshi, Kiichiro Ninomiya, Hisao Higo, Yuka Kato, Masanori Fujii, Toshio Kubo, Eiki Ichihara, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Respiratory medicine case reports   38   101669 - 101669   2022年

    　詳細を見る

    記述言語：英語  

    A 76-year-old woman who was treated with lorlatinib for postoperative recurrent anaplastic lymphoma kinase-positive lung adenocarcinoma visited our hospital with massive hemoptysis. Chest computed tomography showed massive bleeding from the right upper lobe; however, the cause of bleeding was unclear. After bronchial artery embolization (BAE), bronchial occlusion was performed using an Endobronchial Watanabe Spigot (EWS) that was easily placed because BAE had reduced the bleeding volume. Treatment with BAE alone was inadequate; however, additional therapy with EWS after BAE successfully controlled the massive hemoptysis, especially in this patient who underwent lobectomy to prevent respiratory dysfunction.

    DOI： 10.1016/j.rmcr.2022.101669

    PubMed

    researchmap

  • Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report. 国際誌

    Go Makimoto, Atsushi Shimonishi, Kadoaki Ohashi, Kiichiro Ninomiya, Hisao Higo, Yuka Kato, Masanori Fujii, Toshio Kubo, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Case reports in oncology   15 ( 2 )   494 - 498   2022年

    　詳細を見る

    記述言語：英語  

    Tepotinib, the novel MET-tyrosine kinase inhibitor, shows an antitumor effect for patients with non-small-cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation. In January 2022, the AmoyDx® Pan Lung Cancer polymerase chain reaction Panel (AmoyDx® panel), which had a shorter turnaround time than the conventional test, was launched in Japan as a tepotinib companion test. We report a patient with an advanced MET-mutant NSCLC promptly diagnosed using the AmoyDx® panel and successfully treated with tepotinib. Although the patient's performance status (PS) worsened due to the rapid tumor progression and lung abscess formation, the tumor shrank immediately after tepotinib treatment with marked PS improvement.

    DOI： 10.1159/000524326

    PubMed

    researchmap

  • Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors. 国際誌

    Naofumi Hara, Eiki Ichihara, Daijiro Harada, Koji Inoue, Keiichi Fujiwara, Shinobu Hosokawa, Daizo Kishino, Kawai Haruyuki, Nobuaki Ochi, Naohiro Oda, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    Journal of cancer research and clinical oncology   147 ( 12 )   3749 - 3755   2021年12月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1007/s00432-021-03615-5

    Web of Science

    PubMed

    researchmap

  • A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. 国際誌

    Hiroyuki Yasuda, Eiki Ichihara, Jun Sakakibara-Konishi, Yoshitaka Zenke, Shinji Takeuchi, Masahiro Morise, Katsuyuki Hotta, Mineyoshi Sato, Shingo Matsumoto, Azusa Tanimoto, Reiko Matsuzawa, Katuyuki Kiura, Yuta Takashima, Seiji Yano, Junji Koyama, Takahiro Fukushima, Junko Hamamoto, Hideki Terai, Shinnosuke Ikemura, Ryo Takemura, Koichi Goto, Kenzo Soejima

    Lung cancer (Amsterdam, Netherlands)   162   140 - 146   2021年12月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.lungcan.2021.10.006

    Web of Science

    PubMed

    researchmap

  • Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).

    Yukari Tsubata, Kana Watanabe, Ryota Saito, Atsushi Nakamura, Hiroshige Yoshioka, Mami Morita, Ryoichi Honda, Nobuhiro Kanaji, Satoshi Ohizumi, Daisuke Jingu, Taku Nakagawa, Kensuke Nakazawa, Atsuto Mouri, Susumu Takeuchi, Naoki Furuya, Yuki Akazawa, Kiyotaka Miura, Eiki Ichihara, Makoto Maemondo, Satoshi Morita, Kunihiko Kobayashi, Takeshi Isobe

    International journal of clinical oncology   27 ( 1 )   112 - 120   2021年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1007/s10147-021-02043-2

    Web of Science

    PubMed

    researchmap

  • Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease.

    Sachi Okawa, Kammei Rai, Nobuharu Fujii, Yuka Gion, Kiichiro Ninomiya, Yuka Kato, Akihiko Taniguchi, Toshio Kubo, Eiki Ichihara, Kadoaki Ohashi, Nobuaki Miyahara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Internal medicine (Tokyo, Japan)   60 ( 17 )   2831 - 2837   2021年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.2169/internalmedicine.6470-20

    Web of Science

    PubMed

    researchmap

  • SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non-small Cell Lung Cancer. 国際誌

    Hirohisa Kano, Eiki Ichihara, Hiromi Watanabe, Kazuya Nishii, Chihiro Ando, Takamasa Nakasuka, Kiichiro Ninomiya, Yuka Kato, Toshio Kubo, Kammei Rai, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Molecular cancer therapeutics   20 ( 9 )   1653 - 1662   2021年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1158/1535-7163.MCT-20-0965

    Web of Science

    PubMed

    researchmap

  • Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression. 国際誌

    Kazuya Nishii, Kadoaki Ohashi, Hiromi Watanabe, Go Makimoto, Takamasa Nakasuka, Hisao Higo, Kiichiro Ninomiya, Yuka Kato, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Oncology letters   22 ( 3 )   639 - 639   2021年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.3892/ol.2021.12900

    Web of Science

    PubMed

    researchmap

  • Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan: A Case Report.

    Eri Ando, Takamasa Nakasuka, Toshio Kubo, Akihiko Taniguchi, Kiichiro Ninomiya, Yuka Kato, Eiki Ichihara, Kadoaki Ohashi, Kammei Rai, Katsuyuki Hotta, Masaomi Yamane, Nobuaki Miyahara, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Internal medicine (Tokyo, Japan)   61 ( 3 )   379 - 383   2021年8月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    A 16-year-old boy with asthma participated in recovery volunteer work following the 2018 heavy rains in Japan. One month later, he experienced chest pain and dyspnea. Chest computed tomography revealed a cavity with a fungal ball, and Aspergillus fumigatus was detected in his bronchoalveolar lavage fluid. He was treated with voriconazole, but new consolidations appeared rapidly. He also experienced allergic bronchopulmonary aspergillosis. After prednisolone prescription, the consolidations improved; however, his asthma worsened. He underwent partial lung resection to avoid allergens, and his symptoms improved. We must recognize cases of infection after a disaster, especially in patients with chronic respiratory diseases.

    DOI： 10.2169/internalmedicine.7124-21

    PubMed

    researchmap

  • Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404. 国際誌

    Takashi Ninomiya, Naoyuki Nogami, Toshiyuki Kozuki, Daijiro Harada, Toshio Kubo, Kadoaki Ohashi, Eiki Ichihara, Shoichi Kuyama, Kenichiro Kudo, Akihiro Bessho, Makoto Sakugawa, Nobukazu Fujimoto, Keisuke Aoe, Daisuke Minami, Keisuke Sugimoto, Nobuaki Ochi, Nagio Takigawa, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    Japanese journal of clinical oncology   51 ( 8 )   1269 - 1276   2021年8月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1093/jjco/hyab084

    Web of Science

    PubMed

    researchmap

  • Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study. 国際誌

    Hidehito Horinouchi, Naoyuki Nogami, Hideo Saka, Makoto Nishio, Takaaki Tokito, Toshiaki Takahashi, Kazuo Kasahara, Yoshihiro Hattori, Eiki Ichihara, Noriaki Adachi, Kazuo Noguchi, Fabricio Souza, Takayasu Kurata

    Cancer science   112 ( 8 )   3255 - 3265   2021年8月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1111/cas.14980

    Web of Science

    PubMed

    researchmap

  • A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R. 国際誌

    Go Makimoto, Kiichiro Ninomiya, Toshio Kubo, Ryota Sunami, Yuka Kato, Eiki Ichihara, Kadoaki Ohashi, Kammei Rai, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Japanese journal of clinical oncology   51 ( 6 )   956 - 965   2021年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1093/jjco/hyab048

    Web of Science

    PubMed

    researchmap

  • VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers. 国際誌

    Hiromi Watanabe, Eiki Ichihara, Hiroe Kayatani, Go Makimoto, Kiichiro Ninomiya, Kazuya Nishii, Hisao Higo, Chihiro Ando, Sachi Okawa, Takamasa Nakasuka, Hirohisa Kano, Naofumi Hara, Atsuko Hirabae, Yuka Kato, Takashi Ninomiya, Toshio Kubo, Kammei Rai, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Cancer science   112 ( 5 )   1853 - 1864   2021年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1111/cas.14801

    Web of Science

    PubMed

    researchmap

  • The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression. 国際誌

    Nobuaki Ochi, Eiki Ichihara, Nagio Takigawa, Daijiro Harada, Koji Inoue, Takuo Shibayama, Shinobu Hosokawa, Daizo Kishino, Shingo Harita, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    European journal of cancer (Oxford, England : 1990)   149   73 - 81   2021年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.ejca.2021.02.040

    Web of Science

    PubMed

    researchmap

  • 免疫チェックポイント阻害薬投与中、中咽頭癌への放射線照射でアブスコパル効果を認めた肺扁平上皮癌の1例

    中村 香葉, 市原 英基, 柴田 祐作, 村上 悦子, 宮原 信明, 岸野 大蔵

    肺癌   61 ( 2 )   109 - 112   2021年4月

    　詳細を見る

  • Comparison of bronchoscopy and computed tomography-guided needle biopsy for re-biopsy in non-small cell lung cancer patients. 国際誌

    Hirohisa Kano, Toshio Kubo, Kiichiro Ninomiya, Eiki Ichihara, Kadoaki Ohashi, Kammei Rai, Katsuyuki Hotta, Masahiro Tabata, Takao Hiraki, Susumu Kanazawa, Yoshinobu Maeda, Katsuyuki Kiura

    Respiratory investigation   59 ( 2 )   240 - 246   2021年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.resinv.2020.12.001

    Web of Science

    PubMed

    researchmap

  • Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer. 国際誌

    Shinobu Hosokawa, Eiki Ichihara, Akihiro Bessho, Daijiro Harada, Koji Inoue, Takuo Shibayama, Daizo Kishino, Shingo Harita, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    Japanese journal of clinical oncology   51 ( 2 )   279 - 286   2021年2月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1093/jjco/hyaa180

    Web of Science

    PubMed

    researchmap

  • Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial. 国際誌

    Go Makimoto, Katsuyuki Hotta, Isao Oze, Kiichiro Ninomiya, Masamoto Nakanishi, Naofumi Hara, Hirohisa Kano, Hiromi Watanabe, Yusuke Hata, Kazuya Nishii, Takamasa Nakasuka, Junko Itano, Takashi Ninomiya, Toshio Kubo, Kadoaki Ohashi, Eiki Ichihara, Daisuke Minami, Akiko Sato, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Asia-Pacific journal of clinical oncology   17 ( 1 )   101 - 108   2021年2月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1111/ajco.13423

    Web of Science

    PubMed

    researchmap

  • Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors. 国際誌

    Eiki Ichihara, Daijiro Harada, Koji Inoue, Takuo Shibayama, Shinobu Hosokawa, Daizo Kishino, Shingo Harita, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    Cancer immunology, immunotherapy : CII   70 ( 1 )   101 - 106   2021年1月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1007/s00262-020-02662-0

    Web of Science

    PubMed

    researchmap

  • 肺癌診療アップデート：分子標的治療（最近の進歩と残された課題）

    市原 英基

    肺癌   61 ( 5 )   377 - 382   2021年

    　詳細を見る

    記述言語：日本語   出版者・発行元：特定非営利活動法人 日本肺癌学会  

    <p>上皮成長因子受容体（EGFR）遺伝子変異陽性非小細胞肺癌（NSCLC）に対するEGFRチロシンキナーゼ阻害薬（TKI）の有効性が発見されて以来，NSCLCにおける個別化医療は急激に進歩をした．現在，6種類のドライバー遺伝子異常に対する阻害薬が承認されている．これらドライバー遺伝子異常に対する各阻害薬の奏効率はおよそ60～80%，無増悪生存期間は1～2年，時として30カ月を超え，NSCLCの治療を大きく変えた．一方で課題も残されている．検査対象となる遺伝子数が次々と増えている中，検体量や診断確定までの時間が有限である状況で，ドライバー遺伝子をいかにもれなく検出するのか，検査そのものの戦略確立が必要となってきている．また，近年免疫チェックポイント阻害薬では進行NSCLCの治癒の可能性も示唆されているが，分子標的治療ではいまだそのような可能性を示唆する効果は得られておらず，このことも課題に挙げられる．</p>

    DOI： 10.2482/haigan.61.377

    CiNii Article

    researchmap

  • Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. 国際誌

    Toshio Kubo, Hiromi Watanabe, Kiichiro Ninomiya, Kenichiro Kudo, Daisuke Minami, Etsuko Murakami, Nobuaki Ochi, Takashi Ninomiya, Daijiro Harada, Masayuki Yasugi, Eiki Ichihara, Kadoaki Ohashi, Kammei Rai, Keiichi Fujiwara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Japanese journal of clinical oncology   50 ( 12 )   1447 - 1453   2020年12月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1093/jjco/hyaa152

    Web of Science

    PubMed

    researchmap

  • 【COVID-19パンデミックとがん医療への影響】COVID-19における肺炎

    工藤 健一郎, 市原 英基

    癌と化学療法   47 ( 12 )   1657 - 1661   2020年12月

    　詳細を見る

  • Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations. 国際誌

    Hiroe Kayatani, Kadoaki Ohashi, Kiichiro Ninomiya, Go Makimoto, Kazuya Nishii, Hisao Higo, Hiromi Watanabe, Hirohisa Kano, Yuka Kato, Takashi Ninomiya, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Biochemical and biophysical research communications   532 ( 3 )   341 - 346   2020年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.bbrc.2020.07.055

    Web of Science

    PubMed

    researchmap

  • Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834). 国際誌

    Satoru Miura, Takeharu Yamanaka, Terufumi Kato, Satoshi Ikeda, Hidehito Horinouchi, Eiki Ichihara, Masaki Kanazu, Yuichi Takiguchi, Kentaro Tanaka, Yasuhiro Goto, Masafumi Sata, Koichi Hagiwara, Hiroaki Okamoto, Hiroshi Tanaka

    Clinical lung cancer   21 ( 6 )   e592-e596 - E596   2020年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.cllc.2020.05.011

    Web of Science

    PubMed

    researchmap

  • Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab.

    Atsuko Hirabae, Eiki Ichihara, Ryota Sunami, Moeko Ota, Yoshitaka Iwamoto, Yoshinobu Maeda, Katsuyuki Kiura

    Acta medica Okayama   74 ( 5 )   423 - 425   2020年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.18926/AMO/60802

    Web of Science

    PubMed

    researchmap

  • Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status. 国際誌

    Hirohisa Kano, Eiki Ichihara, Daijiro Harada, Koji Inoue, Hiroe Kayatani, Shinobu Hosokawa, Daizo Kishino, Kazuhiko Watanabe, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Kiichiro Ninomiya, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    Cancer science   111 ( 10 )   3739 - 3746   2020年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1111/cas.14590

    Web of Science

    PubMed

    researchmap

  • Association between Histological Types and Enhancement of Dynamic CT for Primary Lung Cancer.

    Shogo Fukuma, Takayoshi Shinya, Junichi Soh, Ryuichiro Fukuhara, Nanako Ogawa, Fumiyo Higaki, Takehiro Tanaka, Eiki Ichihara, Takao Hiraki, Shinichi Toyooka, Susumu Kanazawa

    Acta medica Okayama   74 ( 2 )   129 - 135   2020年4月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.18926/AMO/58271

    Web of Science

    PubMed

    researchmap

  • Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report. 国際誌

    Natsumi Matsuoka, Kenji Tsuji, Eiki Ichihara, Takayuki Hara, Kazuhiko Fukushima, Kishio Toma, Shinji Kitamura, Kenichi Inagaki, Hitoshi Sugiyama, Jun Wada

    BMC nephrology   21 ( 1 )   113 - 113   2020年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1186/s12882-020-01775-z

    Web of Science

    PubMed

    researchmap

  • Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. 国際誌

    Kiichiro Ninomiya, Isao Oze, Yuka Kato, Toshio Kubo, Eiki Ichihara, Kammei Rai, Kadoaki Ohashi, Toshiyuki Kozuki, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura, Katsuyuki Hotta

    Acta oncologica (Stockholm, Sweden)   59 ( 3 )   249 - 256   2020年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1080/0284186X.2019.1695062

    Web of Science

    PubMed

    researchmap

  • Patients' preferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406. 国際誌

    Go Makimoto, Katsuyuki Hotta, Isao Oze, Kiichiro Ninomiya, Masamoto Nakanishi, Naofumi Hara, Hirohisa Kano, Hiromi Watanabe, Yusuke Hata, Kazuya Nishii, Takamasa Nakasuka, Junko Itano, Takashi Ninomiya, Toshio Kubo, Kadoaki Ohashi, Eiki Ichihara, Daisuke Minami, Akiko Sato, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Acta oncologica (Stockholm, Sweden)   59 ( 3 )   324 - 328   2020年3月

    　詳細を見る

  • Managing Lung Cancer with Comorbid Interstitial Pneumonia.

    Eiki Ichihara, Nobuaki Miyahara, Yoshinobu Maeda, Katsuyuki Kiura

    Internal medicine (Tokyo, Japan)   59 ( 2 )   163 - 167   2020年1月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.2169/internalmedicine.3481-19

    Web of Science

    PubMed

    researchmap

  • The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. 国際誌

    Eiki Ichihara, Daijiro Harada, Koji Inoue, Ken Sato, Shinobu Hosokawa, Daizo Kishino, Kazuhiko Watanabe, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    Lung cancer (Amsterdam, Netherlands)   139   140 - 145   2020年1月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.lungcan.2019.11.011

    Web of Science

    PubMed

    researchmap

  • Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden. 国際誌

    Go Makimoto, Kadoaki Ohashi, Shuta Tomida, Kazuya Nishii, Takehiro Matsubara, Hiroe Kayatani, Hisao Higo, Kiichiro Ninomiya, Akiko Sato, Hiromi Watanabe, Hirohisa Kano, Takashi Ninomiya, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Shinichi Toyooka, Minoru Takata, Yoshinobu Maeda, Katsuyuki Kiura

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer   14 ( 11 )   2009 - 2018   2019年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.jtho.2019.07.017

    Web of Science

    PubMed

    researchmap

  • Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. 国際誌

    Takashi Ogura, Nagio Takigawa, Keisuke Tomii, Kazuma Kishi, Yoshikazu Inoue, Eiki Ichihara, Sakae Homma, Kazuhisa Takahashi, Hiroaki Akamatsu, Satoshi Ikeda, Naohiko Inase, Tae Iwasawa, Yuichiro Ohe, Hiromitsu Ohta, Hiroshi Onishi, Isamu Okamoto, Kazumasa Ogawa, Kazuo Kasahara, Hiroki Karata, Takumi Kishimoto, Yuka Kitamura, Akihiko Gemma, Hirotsugu Kenmotsu, Hiroyuki Sakashita, Susumu Sakamoto, Katsutoshi Sekine, Yuichi Takiguchi, Yuji Tada, Shinichi Toyooka, Yuko Nakayama, Yasuhiko Nishioka, Koichi Hagiwara, Masaki Hanibuchi, Junya Fukuoka, Yuji Minegishi, Toyoshi Yanagihara, Nobuyuki Yamamoto, Hiromasa Yamamoto, Mina Gaga, Kwun M Fong, Charles A Powell, Katsuyuki Kiura

    Respiratory investigation   57 ( 6 )   512 - 533   2019年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.resinv.2019.06.001

    Web of Science

    PubMed

    researchmap

  • Granulation Tissue-induced Pseudo-relapse During Nivolumab Treatment in Advanced Non-small Cell Lung Cancer

    Chihiro Ando, Eiki Ichihara, Hirohisa Kano, Yoshitaka Iwamoto, Atsuko Hirabae, Takamasa Nakasuka, Yoshinobu Maeda, Katsuyuki Kiura

    IN VIVO   33 ( 6 )   2113 - 2115   2019年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.21873/invivo.11711

    Web of Science

    researchmap

  • KEYNOTE-189試験における日本人転移性NSCLC患者に対するpembrolizumab+pemetrexed/platinum併用療法(Pembrolizumab Plus Pemetrexed-Platinum for Metastatic NSCLC Among Japanese Patients in KEYNOTE-189)

    野上 尚之, Horinouchi Hidehito, Saka Hideo, Nishio Makoto, Tokito Takaaki, Takahashi Toshiaki, Kasahara Kazuo, Hattori Yoshihiro, Ichihara Eiki, Adachi Noriaki, Noguchi Kazuo, Souza Fabricio, Kurata Takayasu

    肺癌   59 ( 6 )   540 - 540   2019年11月

    　詳細を見る

    記述言語：英語   出版者・発行元：(NPO)日本肺癌学会  

    researchmap

  • Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies. 国際誌

    Kazuya Nishii, Katsuyuki Hotta, Kiichiro Ninomiya, Yuka Kato, Eiki Ichihara, Kadoaki Ohashi, Takashi Ninomiya, Toshio Kubo, Kammei Rai, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Respiratory investigation   57 ( 5 )   460 - 465   2019年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.resinv.2019.04.004

    Web of Science

    PubMed

    researchmap

  • The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. 国際誌

    Hiromi Watanabe, Toshio Kubo, Kiichiro Ninomiya, Kenichiro Kudo, Daisuke Minami, Etsuko Murakami, Nobuaki Ochi, Takashi Ninomiya, Daijiro Harada, Masayuki Yasugi, Eiki Ichihara, Kadoaki Ohashi, Keiichi Fujiwara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Japanese journal of clinical oncology   49 ( 8 )   762 - 765   2019年8月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1093/jjco/hyz066

    Web of Science

    PubMed

    researchmap

  • Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation. 国際誌

    Yoshitaka Iwamoto, Eiki Ichihara, Naofumi Hara, Takamasa Nakasuka, Chihiro Ando, Takahiro Umeno, Atsuko Hirabae, Yoshinobu Maeda, Katsuyuki Kiura

    Japanese journal of clinical oncology   49 ( 8 )   786 - 788   2019年8月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1093/jjco/hyz086

    Web of Science

    PubMed

    researchmap

  • Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma. 国際誌

    Takamasa Nakasuka, Eiki Ichihara, Go Makimoto, Yoshinobu Maeda, Katsuyuki Kiura

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer   14 ( 8 )   e168-e169 - E169   2019年8月

    　詳細を見る

  • Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer. 国際誌

    Eiki Ichihara, Katsuyuki Hotta, Kiichiro Ninomiya, Toshio Kubo, Kadoaki Ohashi, Kammei Rai, Hisaaki Tanaka, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Lung cancer (Amsterdam, Netherlands)   132   54 - 58   2019年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.lungcan.2019.02.021

    Web of Science

    PubMed

    researchmap

  • Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities. 国際誌

    Hisao Higo, Toshio Kubo, Satoko Makimoto, Go Makimoto, Hiroki Ihara, Yoshihisa Masaoka, Takashi Ninomiya, Eiki Ichihara, Kadoaki Ohashi, Akiko Sato, Katsuyuki Hotta, Masahiro Tabata, Nagio Takigawa, Yoshinobu Maeda, Katsuyuki Kiura

    Japanese journal of clinical oncology   49 ( 5 )   458 - 464   2019年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1093/jjco/hyz016

    Web of Science

    PubMed

    researchmap

  • Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities

    Hisao Higo, Toshio Kubo, Satoko Makimoto, Go Makimoto, Hiroki Ihara, Yoshihisa Masaoka, Takashi Ninomiya, Eiki Ichihara, Kadoaki Ohashi, Akiko Sato, Katsuyuki Hotta, Masahiro Tabata, Nagio Takigawa, Yoshinobu Maeda, Katsuyuki Kiura

    JAPANESE JOURNAL OF CLINICAL ONCOLOGY   49 ( 5 )   458 - 464   2019年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1093/jjco/hyz016

    Web of Science

    researchmap

  • Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice.

    Katsuyuki Hotta, Kiichiro Ninomiya, Eiki Ichihara, Katsuyuki Kiura

    International journal of clinical oncology   24 ( 1 )   41 - 45   2019年1月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1007/s10147-018-1344-x

    Web of Science

    PubMed

    researchmap

  • A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403. 国際誌

    Naohiro Oda, Kastuyuki Hotta, Kiichiro Ninomiya, Daisuke Minami, Eiki Ichihara, Toshi Murakami, Toshihide Yokoyama, Hirohisa Ichikawa, Kenichi Chikamori, Nagio Takigawa, Nobuaki Ochi, Shingo Harita, Yoshinobu Maeda, Katsuyuki Kiura

    Cancer chemotherapy and pharmacology   82 ( 6 )   1031 - 1038   2018年12月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1007/s00280-018-3694-5

    Web of Science

    PubMed

    researchmap

  • Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions. 国際誌

    Yuka Kato, Kiichiro Ninomiya, Kadoaki Ohashi, Shuta Tomida, Go Makimoto, Hiromi Watanabe, Kenichiro Kudo, Shingo Matsumoto, Shigeki Umemura, Koichi Goto, Eiki Ichihara, Takashi Ninomiya, Toshio Kubo, Akiko Sato, Katsuyuki Hotta, Masahiro Tabata, Shinichi Toyooka, Yoshinobu Maeda, Katsuyuki Kiura

    Cancer science   109 ( 10 )   3149 - 3158   2018年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1111/cas.13752

    Web of Science

    PubMed

    researchmap

  • Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer. 国際誌

    Eiki Ichihara, Katsuyuki Hotta, Toshio Kubo, Tsukasa Higashionna, Kiichiro Ninomiya, Kadoaki Ohashi, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Oncotarget   9 ( 50 )   29525 - 29531   2018年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Background: Osimertinib is an essential drug to treat non-small-cell lung cancer (NSCLC) harboring the epidermal growth factor receptor (EGFR) T790M mutation, and rebiopsy is necessary to detect this mutation. However, the significance of repeat rebiopsy in NSCLC patients whose first rebiopsy was T790M-negative remains unclear. We used a retrospective cohort to clarify this issue. Methods: We reviewed the medical records of patients with NSCLC harboring EGFR mutations who underwent EGFR tyrosine kinase inhibitor (TKI) treatment at Okayama University Hospital between January 2015 and January 2017. Results: Of 102 patients with EGFR-mutant NSCLC, 55 underwent rebiopsy after acquired resistance to prior EGFR TKIs. Pre-existing activating EGFR mutations were found in all 55 rebiopsied samples. Of the 55 samples, 25 were T790M-positive (45%). Among the remaining 30 patients (T790M-negative on the first rebiopsy), 21 underwent additional rebiopsies following interval therapy. Of the 21 patients, 11 were T790M-positive on the second rebiopsy and 1 on the third. We also evaluated the efficacy of osimertinib in patients who needed a repeat rebiopsy to detect the T790M mutation. Osimertinib showed good activity with an objective response rate of 50%. Conclusions: Repeat rebiopsy increases the ability to detect a secondary mutation (T790M) in EGFR.

    DOI： 10.18632/oncotarget.25705

    PubMed

    researchmap

  • Randomized Phase II Study Comparing Mannitol with Furosemide for the Prevention of Renal Toxicity Induced by Cisplatin-based Chemotherapy with Short-term Low-volume Hydration in Advanced Non-small Cell Lung Cancer: The OLCSG1406 Study Protocol.

    Go Makimoto, Eiki Ichihara, Katsuyuki Hotta, Kiichiro Ninomiya, Isao Oze, Daisuke Minami, Takashi Ninomiya, Toshio Kubo, Kadoaki Ohashi, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Acta medica Okayama   72 ( 3 )   319 - 323   2018年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.18926/AMO/56080

    Web of Science

    PubMed

    researchmap

  • A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer. 国際誌

    Katsuyuki Hotta, Keisuke Aoe, Toshiyuki Kozuki, Kadoaki Ohashi, Kiichiro Ninomiya, Eiki Ichihara, Toshio Kubo, Takashi Ninomiya, Kenichi Chikamori, Daijiro Harada, Naoyuki Nogami, Taizo Hirata, Shiro Hinotsu, Shinichi Toyooka, Katsuyuki Kiura

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer   13 ( 2 )   273 - 279   2018年2月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.jtho.2017.10.032

    Web of Science

    PubMed

    researchmap

  • MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. 国際誌

    Kiichiro Ninomiya, Kadoaki Ohashi, Go Makimoto, Shuta Tomida, Hisao Higo, Hiroe Kayatani, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Scientific reports   8 ( 1 )   1955 - 1955   2018年1月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1038/s41598-018-20326-z

    Web of Science

    PubMed

    researchmap

  • Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. 国際誌

    Tomoki Tamura, Yuka Kato, Kadoaki Ohashi, Kiichiro Ninomiya, Go Makimoto, Hiroko Gotoda, Toshio Kubo, Eiki Ichihara, Takehiro Tanaka, Koichi Ichimura, Yoshinobu Maeda, Katsuyuki Hotta, Katsuyuki Kiura

    Biochemical and biophysical research communications   495 ( 1 )   360 - 367   2018年1月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.bbrc.2017.10.175

    Web of Science

    PubMed

    researchmap

  • Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis. 国際誌

    Kohei Otsubo, Junji Kishimoto, Hirotsugu Kenmotsu, Yuji Minegishi, Eiki Ichihara, Akira Shiraki, Terufumi Kato, Shinji Atagi, Hidehito Horinouchi, Masahiko Ando, Yasuhiro Kondoh, Masahiko Kusumoto, Kazuya Ichikado, Nobuyuki Yamamoto, Yoichi Nakanishi, Isamu Okamoto

    Clinical lung cancer   19 ( 1 )   e5-e9 - E9   2018年1月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.cllc.2017.06.003

    Web of Science

    PubMed

    researchmap

  • Effects of (-)-epigallocatechin-3-gallate on EGFR- or Fusion Gene-driven Lung Cancer Cells.

    Yoshihiro Honda, Nagio Takigawa, Eiki Ichihara, Takashi Ninomiya, Toshio Kubo, Nobuaki Ochi, Masayuki Yasugi, Toshi Murakami, Hiromichi Yamane, Mitsune Tanimoto, Katsuyuki Kiura

    Acta medica Okayama   71 ( 6 )   505 - 512   2017年12月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.18926/AMO/55587

    Web of Science

    PubMed

    researchmap

  • Protective Effects of Bisoprolol against Acute Exacerbation in Moderate-to-Severe Chronic Obstructive Pulmonary Disease.

    Akihiko Taniguchi, Nobuaki Miyahara, Naohiro Oda, Daisuke Morichika, Eiki Ichihara, Isao Oze, Yasushi Tanimoto, Hirohisa Ichikawa, Utako Fujii, Mitsune Tanimoto, Arihiko Kanehiro, Katsuyuki Kiura

    Acta medica Okayama   71 ( 5 )   453 - 457   2017年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.18926/AMO/55446

    Web of Science

    PubMed

    researchmap

  • A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202. 国際誌

    Shoichi Kuyama, Nobuaki Ochi, Akihiro Bessho, Katsuyuki Hotta, Genyo Ikeda, Daizo Kishino, Toshio Kubo, Daijiro Harada, Nobukazu Fujimoto, Masamoto Nakanishi, Takahiro Umeno, Toshiaki Okada, Kenichi Chikamori, Tomoko Yamagishi, Kadoaki Ohashi, Eiki Ichihara, Nagio Takigawa, Mitsune Tanimoto, Katsuyuki Kiura

    Lung cancer (Amsterdam, Netherlands)   112   188 - 194   2017年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.lungcan.2017.08.010

    Web of Science

    PubMed

    researchmap

  • Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC).

    Hiromi Watanabe, Eiki Ichihara, Hirohisa Kano, Kiichiro Ninomiya, Mitsune Tanimoto, Katsuyuki Kiura

    Internal medicine (Tokyo, Japan)   56 ( 16 )   2195 - 2197   2017年8月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.2169/internalmedicine.8344-16

    Web of Science

    PubMed

    researchmap

  • Clinical characteristics of Japanese candidates for lung transplant for interstitial lung disease and risk factors for early death while on the waiting list. 国際誌

    Hisao Higo, Takeshi Kurosaki, Eiki Ichihara, Toshio Kubo, Kentaroh Miyoshi, Shinji Otani, Seiichiro Sugimoto, Masaomi Yamane, Nobuaki Miyahara, Katsuyuki Kiura, Shinichiro Miyoshi, Takahiro Oto

    Respiratory investigation   55 ( 4 )   264 - 269   2017年7月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.resinv.2017.03.002

    Web of Science

    PubMed

    researchmap

  • SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. 国際誌

    Eiki Ichihara, David Westover, Catherine B Meador, Yingjun Yan, Joshua A Bauer, Pengcheng Lu, Fei Ye, Amanda Kulick, Elisa de Stanchina, Robert McEwen, Marc Ladanyi, Darren Cross, William Pao, Christine M Lovly

    Cancer research   77 ( 11 )   2990 - 3000   2017年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1158/0008-5472.CAN-16-2300

    Web of Science

    PubMed

    researchmap

  • Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo. 国際誌

    Kenichiro Kudo, Kadoaki Ohashi, Go Makimoto, Hisao Higo, Yuka Kato, Hiroe Kayatani, Yasuko Kurata, Yoichiro Takami, Daisuke Minami, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Akiko Sato, Katsuyuki Hotta, Tadashi Yoshino, Mitsune Tanimoto, Katsuyuki Kiura

    Molecular oncology   11 ( 6 )   670 - 681   2017年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1002/1878-0261.12063

    Web of Science

    PubMed

    researchmap

  • Discomfort during bronchoscopy performed after endobronchial intubation with fentanyl and midazolam: a prospective study. 国際誌

    Daisuke Minami, Nagio Takigawa, Hirohisa Kano, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Kadoaki Ohashi, Akiko Sato, Katsuyuki Hotta, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura

    Japanese journal of clinical oncology   47 ( 5 )   434 - 437   2017年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1093/jjco/hyx022

    Web of Science

    PubMed

    researchmap

  • Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol. 国際誌

    Kiichiro Ninomiya, Eiki Ichihara, Katsuyuki Hotta, Naoyuki Sone, Toshi Murakami, Daijiro Harada, Isao Oze, Toshio Kubo, Hisaaki Tanaka, Shoichi Kuyama, Daizo Kishino, Akihiro Bessho, Shingo Harita, Kuniaki Katsui, Mitsune Tanimoto, Katsuyuki Kiura

    Clinical lung cancer   18 ( 2 )   245 - 249   2017年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.cllc.2016.08.001

    Web of Science

    PubMed

    researchmap

  • Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403. 国際誌

    Naohiro Oda, Eiki Ichihara, Katsuyuki Hotta, Kiichiro Ninomiya, Takashi Ninomiya, Toshio Kubo, Daisuke Minami, Toshi Murakami, Toshihide Yokoyama, Daijiro Harada, Shoichi Kuyama, Hirohisa Ichikawa, Koji Inoue, Daizo Kishino, Masaaki Inoue, Nagio Takigawa, Takuo Shibayama, Shingo Harita, Mitsune Tanimoto, Katsuyuki Kiura

    Clinical lung cancer   18 ( 2 )   241 - 244   2017年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.cllc.2016.07.003

    Web of Science

    PubMed

    researchmap

  • Safety And Discomfort During Bronchoscopy Performed Under Sedation With Fentanyl And Midazolam: A Prospective Study 査読

    D. Minami, N. Takigawa, T. Ninomiya, T. Kubo, E. Ichihara, K. Ohashi, A. Sato, K. Hotta, T. Shibayama, N. Miyahara, M. Tabata, A. Kanehiro, K. Kiura

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE   195 ( 9 )   871 - 874   2017年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1093/jjco/hyw083

    Web of Science

    researchmap

  • Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405). 国際誌

    Hideko Isozaki, Katsuyuki Hotta, Eiki Ichihara, Nagio Takigawa, Kadoaki Ohashi, Toshio Kubo, Takashi Ninomiya, Kiichiro Ninomiya, Naohiro Oda, Hiroshige Yoshioka, Hirohisa Ichikawa, Masaaki Inoue, Ichiro Takata, Takuo Shibayama, Shoichi Kuyama, Keisuke Sugimoto, Daijiro Harada, Shingo Harita, Toshiaki Sendo, Mitsune Tanimoto, Katsuyuki Kiura

    Clinical lung cancer   17 ( 6 )   602 - 605   2016年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.cllc.2016.05.005

    Web of Science

    PubMed

    researchmap

  • Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. 国際誌

    Naohiro Oda, Katsuyuki Hotta, Hiroshige Yoshioka, Kenichiro Kudo, Eiki Ichihara, Yuka Kato, Kiichiro Ninomiya, Daisuke Minami, Takashi Ninomiya, Toshio Kubo, Kadoaki Ohashi, Akiko Sato, Nagio Takigawa, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura

    Cancer chemotherapy and pharmacology   78 ( 5 )   941 - 947   2016年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1007/s00280-016-3146-z

    Web of Science

    PubMed

    researchmap

  • Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation.

    Masahiro Osawa, Kadoaki Ohashi, Toshio Kubo, Eiki Ichihara, Saburo Takata, Nagio Takigawa, Minoru Takata, Mitsune Tanimoto, Katsuyuki Kiura

    Acta medica Okayama   70 ( 4 )   243 - 53   2016年8月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Web of Science

    PubMed

    researchmap

  • EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. 国際誌

    Kartik Konduri, Jean-Nicolas Gallant, Young Kwang Chae, Francis J Giles, Barbara J Gitlitz, Kyle Gowen, Eiki Ichihara, Taofeek K Owonikoko, Vijay Peddareddigari, Suresh S Ramalingam, Satyanarayan K Reddy, Beth Eaby-Sandy, Tiziana Vavalà, Andrew Whiteley, Heidi Chen, Yingjun Yan, Jonathan H Sheehan, Jens Meiler, Deborah Morosini, Jeffrey S Ross, Philip J Stephens, Vincent A Miller, Siraj M Ali, Christine M Lovly

    Cancer discovery   6 ( 6 )   601 - 11   2016年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1158/2159-8290.CD-16-0075

    Web of Science

    PubMed

    researchmap

  • Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. 国際誌

    Hideko Isozaki, Eiki Ichihara, Nagio Takigawa, Kadoaki Ohashi, Nobuaki Ochi, Masayuki Yasugi, Takashi Ninomiya, Hiromichi Yamane, Katsuyuki Hotta, Katsuya Sakai, Kunio Matsumoto, Shinobu Hosokawa, Akihiro Bessho, Toshiaki Sendo, Mitsune Tanimoto, Katsuyuki Kiura

    Cancer research   76 ( 6 )   1506 - 16   2016年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1158/0008-5472.CAN-15-1010

    Web of Science

    PubMed

    researchmap

  • インターロイキン-6はEGFRに変異を有する進行性のNSCLC患者におけるゲフィチニブの治療効果に関する価値のある予測マーカである(Interleukin6 is a Valuable Predictive Marker for Therapeutic Effect of Gefitinib in Patients with Advanced NSCLC Harboring EGFR mutations)

    Tamura Tomoki, Hotta Katsuyuki, Kato Yuka, Gotoda Hiroko, Tanaka Takehiro, Ichimura Koichi, Kubo Toshio, Ohashi Kadoaki, Ichihara Eiki, Kiura Katsuyuki

    日本呼吸器学会誌   5 ( 増刊 )   373 - 373   2016年3月

    　詳細を見る

    記述言語：英語   出版者・発行元：(一社)日本呼吸器学会  

    researchmap

  • Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201.

    Kiichiro Ninomiya, Katsuyuki Hotta, Akiko Hisamoto-Sato, Eiki Ichihara, Hiroko Gotoda, Daisuke Morichika, Tomoki Tamura, Hiroe Kayatani, Daisuke Minami, Toshio Kubo, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura

    International journal of clinical oncology   21 ( 1 )   81 - 7   2016年2月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1007/s10147-015-0860-1

    Web of Science

    PubMed

    researchmap

  • Short-term low-volume hydration in cisplatin-based chemotherapy: a feasibility study in lung cancer (OLCSG1201)

    Kiichiro Ninomiya, Katsuyuki Hotta, Hiroko Gotoda, Daisuke Morichika, Eiki Ichihara, Akiko Sato, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura

    ANNALS OF ONCOLOGY   26   80 - 80   2015年11月

    　詳細を見る

    記述言語：英語  

    Web of Science

    researchmap

  • RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. 国際誌

    Gorjan Hrustanovic, Victor Olivas, Evangelos Pazarentzos, Asmin Tulpule, Saurabh Asthana, Collin M Blakely, Ross A Okimoto, Luping Lin, Dana S Neel, Amit Sabnis, Jennifer Flanagan, Elton Chan, Marileila Varella-Garcia, Dara L Aisner, Aria Vaishnavi, Sai-Hong I Ou, Eric A Collisson, Eiki Ichihara, Philip C Mack, Christine M Lovly, Niki Karachaliou, Rafael Rosell, Jonathan W Riess, Robert C Doebele, Trever G Bivona

    Nature medicine   21 ( 9 )   1038 - 47   2015年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1038/nm.3930

    Web of Science

    PubMed

    researchmap

  • Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703. 国際誌

    Kenichiro Kudo, Katsuyuki Hotta, Eiki Ichihara, Hiroshige Yoshioka, Kei Kunimasa, Kazuya Tsubouchi, Masahiro Iwasaku, Yuka Kato, Isao Oze, Nagio Takigawa, Mitsune Tanimoto, Katsuyuki Kiura

    Cancer chemotherapy and pharmacology   76 ( 2 )   251 - 6   2015年8月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1007/s00280-015-2789-5

    Web of Science

    PubMed

    researchmap

  • Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer. 国際誌

    Eiki Ichihara, Christine M Lovly

    Cancer discovery   5 ( 7 )   694 - 6   2015年7月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1158/2159-8290.CD-15-0616

    Web of Science

    PubMed

    researchmap

  • Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. 国際誌

    Catherine A Eberlein, Daniel Stetson, Aleksandra A Markovets, Katherine J Al-Kadhimi, Zhongwu Lai, Paul R Fisher, Catherine B Meador, Paula Spitzler, Eiki Ichihara, Sarah J Ross, Miika J Ahdesmaki, Ambar Ahmed, Laura E Ratcliffe, Elizabeth L Christey O'Brien, Claire H Barnes, Henry Brown, Paul D Smith, Jonathan R Dry, Garry Beran, Kenneth S Thress, Brian Dougherty, William Pao, Darren A E Cross

    Cancer research   75 ( 12 )   2489 - 500   2015年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1158/0008-5472.CAN-14-3167

    Web of Science

    PubMed

    researchmap

  • Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. 国際誌

    Eiki Ichihara, Katsuyuki Hotta, Naoyuki Nogami, Shoichi Kuyama, Daizo Kishino, Masanori Fujii, Toshiyuki Kozuki, Masahiro Tabata, Daijiro Harada, Kenichi Chikamori, Keisuke Aoe, Hiroshi Ueoka, Shinobu Hosokawa, Akihiro Bessho, Akiko Hisamoto-Sato, Toshio Kubo, Isao Oze, Nagio Takigawa, Mitsune Tanimoto, Katsuyuki Kiura

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer   10 ( 3 )   486 - 91   2015年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1097/JTO.0000000000000434

    Web of Science

    PubMed

    researchmap

  • 活性化型の上皮増殖因子受容体(EGFR)変異を有する肺がん細胞における低用量アファチニブとセツキシマブの併用療法に対するベバシズマブの効果(The impact of bevacizumab on combination low-dose afatinib and cetuximab therapy in lung cancer cells harboring activated EGFR mutations)

    Kudo Kenichiro, Ohashi Kadoaki, Ichihara Eiki, Kubo Hisao, Minami Daisuke, Hisamoto Akiko, Hotta Katsuyuki, Tanimoto Mitsune, Kiura Katsuyuki

    日本呼吸器学会誌   4 ( 増刊 )   348 - 348   2015年3月

    　詳細を見る

    記述言語：英語   出版者・発行元：(一社)日本呼吸器学会  

    researchmap

  • A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene. 国際誌

    Hideko Isozaki, Masayuki Yasugi, Nagio Takigawa, Katsuyuki Hotta, Eiki Ichihara, Akihiko Taniguchi, Shinichi Toyooka, Shinsuke Hashida, Toshiaki Sendo, Mitsune Tanimoto, Katsuyuki Kiura

    Japanese journal of clinical oncology   44 ( 10 )   963 - 8   2014年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1093/jjco/hyu110

    Web of Science

    PubMed

    researchmap

  • AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. 国際誌

    Darren A E Cross, Susan E Ashton, Serban Ghiorghiu, Cath Eberlein, Caroline A Nebhan, Paula J Spitzler, Jonathon P Orme, M Raymond V Finlay, Richard A Ward, Martine J Mellor, Gareth Hughes, Amar Rahi, Vivien N Jacobs, Monica Red Brewer, Eiki Ichihara, Jing Sun, Hailing Jin, Peter Ballard, Katherine Al-Kadhimi, Rachel Rowlinson, Teresa Klinowska, Graham H P Richmond, Mireille Cantarini, Dong-Wan Kim, Malcolm R Ranson, William Pao

    Cancer discovery   4 ( 9 )   1046 - 61   2014年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1158/2159-8290.CD-14-0337

    Web of Science

    PubMed

    researchmap

  • Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors. 国際誌

    Masayuki Yasugi, Nagio Takigawa, Nobuaki Ochi, Kadoaki Ohashi, Daijiro Harada, Takashi Ninomiya, Toshi Murakami, Yoshihiro Honda, Eiki Ichihara, Mitsune Tanimoto, Katsuyuki Kiura

    Experimental cell research   326 ( 2 )   201 - 9   2014年8月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.yexcr.2014.04.012

    Web of Science

    PubMed

    researchmap

  • Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience. 国際誌

    Yuka Kato, Katsuyuki Hotta, Nagio Takigawa, Naoyuki Nogami, Toshiyuki Kozuki, Akiko Sato, Eiki Ichihara, Kenichiro Kudo, Isao Oze, Masahiro Tabata, Tetsu Shinkai, Mitsune Tanimoto, Katsuyuki Kiura

    Cancer chemotherapy and pharmacology   73 ( 5 )   943 - 50   2014年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1007/s00280-014-2425-9

    Web of Science

    PubMed

    researchmap

  • Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer. 国際誌

    Nobuaki Ochi, Nagio Takigawa, Daijiro Harada, Masayuki Yasugi, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura

    Experimental cell research   322 ( 1 )   168 - 77   2014年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.yexcr.2014.01.007

    Web of Science

    PubMed

    researchmap

  • Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer 査読

    Nobuaki Ochi, Nagio Takigawa, Daijiro Harada, Masayuki Yasugi, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura

    Experimental cell research   322 ( 1 )   168 - 177   2014年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Elsevier  

    To study epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance mechanisms, we established a novel gefitinib-resistant lung cancer cell line derived from an EGFR-mutant non-small cell lung cancer cell line (PC-9) pretreated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (designated PC9-GR). We found that gefitinib substantially suppressed the EGFR signaling pathway, whereas ERK was reactivated after several hours in PC9-GR but not in PC-9. The combination of gefitinib with ERK inhibition (by U0126) restored gefitinib susceptibility in PC9-GR, but PI3K-Akt inhibition with LY294002 did not. Although the levels of phosphorylated Src were up-regulated simultaneously with ERK reactivation, neither ERK suppression using U0126 nor an ERK-specific siRNA induced Src phosphorylation. Furthermore, dual inhibition of EGFR and Src restored gefitinib sensitivity in PC9-GR in vitro and in vivo. In conclusion, our results indicate that Src-mediated ERK reactivation may play a role in a novel gefitinib resistance mechanism, and that the combined use of gefitinib with a Src inhibitor may be a potent strategy to overcome this resistance.

    DOI： 10.1016/j.yexcr.2014.01.007

    PubMed

    CiNii Article

    researchmap

  • Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model. 国際誌

    Toshi Murakami, Nagio Takigawa, Takashi Ninomiya, Nobuaki Ochi, Masaaki Yasugi, Yoshihiro Honda, Toshio Kubo, Eiki Ichihara, Katsuyuki Hotta, Mitsune Tanimoto, Katsuyuki Kiura

    Lung cancer (Amsterdam, Netherlands)   83 ( 1 )   30 - 6   2014年1月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.lungcan.2013.10.011

    Web of Science

    PubMed

    researchmap

  • Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model. 国際誌

    Hiromi Hayakawa, Eiki Ichihara, Kadoaki Ohashi, Takashi Ninomiya, Masayuki Yasugi, Saburo Takata, Katsuya Sakai, Kunio Matsumoto, Nagio Takigawa, Mitsune Tanimoto, Katsuyuki Kiura

    Cancer science   104 ( 11 )   1440 - 6   2013年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1111/cas.12284

    Web of Science

    PubMed

    researchmap

  • Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002. 国際誌

    Katsuyuki Hotta, Nagio Takigawa, Akiko Hisamoto-Sato, Eiki Ichihara, Kenichiro Kudo, Koji Uchida, Kayo Yanase-Nakamura, Hisaaki Tanaka, Yuka Kato, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura

    Japanese journal of clinical oncology   43 ( 11 )   1115 - 23   2013年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1093/jjco/hyt128

    Web of Science

    PubMed

    researchmap

  • Usefulness of endobronchial ultrasound-guided transbronchial needle aspiration in distinguishing sarcoidosis from recurrent cancer in patients with lymphadenopathy after surgery. 国際誌

    Daisuke Minami, Nagio Takigawa, Hiromi Hayakawa, Makoto Mizuta, Kenichiro Kudo, Kozi Uchida, Eiki Ichihara, Akiko Sato, Katsuyuki Hotta, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura

    Japanese journal of clinical oncology   43 ( 11 )   1110 - 4   2013年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1093/jjco/hyt123

    Web of Science

    PubMed

    researchmap

  • Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. 国際誌

    Eiki Ichihara, Katsuyuki Hotta, Nagio Takigawa, Kenichiro Kudo, Yuka Kato, Yoshihiro Honda, Hiromi Hayakawa, Daisuke Minami, Akiko Sato, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura

    Lung cancer (Amsterdam, Netherlands)   81 ( 3 )   435 - 439   2013年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.lungcan.2013.05.021

    Web of Science

    PubMed

    researchmap

  • Antitumor impact of p14ARF on gefitinib-resistant non-small cell lung cancers. 国際誌

    Ken Saito, Nagio Takigawa, Naoko Ohtani, Hidekazu Iioka, Yuki Tomita, Ryuzo Ueda, Junya Fukuoka, Kazuhiko Kuwahara, Eiki Ichihara, Katsuyuki Kiura, Eisaku Kondo

    Molecular cancer therapeutics   12 ( 8 )   1616 - 28   2013年8月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1158/1535-7163.MCT-12-1239

    Web of Science

    PubMed

    researchmap

  • Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. 国際誌

    Kazuhiko Shien, Shinichi Toyooka, Hiromasa Yamamoto, Junichi Soh, Masaru Jida, Kelsie L Thu, Shinsuke Hashida, Yuho Maki, Eiki Ichihara, Hiroaki Asano, Kazunori Tsukuda, Nagio Takigawa, Katsuyuki Kiura, Adi F Gazdar, Wan L Lam, Shinichiro Miyoshi

    Cancer research   73 ( 10 )   3051 - 61   2013年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1158/0008-5472.CAN-12-4136

    Web of Science

    PubMed

    researchmap

  • Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. 国際誌

    Takashi Ninomiya, Nagio Takigawa, Eiki Ichihara, Nobuaki Ochi, Toshi Murakami, Yoshihiro Honda, Toshio Kubo, Daisuke Minami, Kenichiro Kudo, Mitsune Tanimoto, Katsuyuki Kiura

    Molecular cancer therapeutics   12 ( 5 )   589 - 97   2013年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1158/1535-7163.MCT-12-0885

    Web of Science

    PubMed

    researchmap

  • Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. 国際誌

    Hiromasa Takeda, Nagio Takigawa, Kadoaki Ohashi, Daisuke Minami, Itaru Kataoka, Eiki Ichihara, Nobuaki Ochi, Mitsune Tanimoto, Katsuyuki Kiura

    Experimental cell research   319 ( 4 )   417 - 23   2013年2月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.yexcr.2012.12.018

    Web of Science

    PubMed

    researchmap

  • Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. 国際誌

    Daisuke Minami, Nagio Takigawa, Hiromasa Takeda, Minoru Takata, Nobuaki Ochi, Eiki Ichihara, Akiko Hisamoto, Katsuyuki Hotta, Mitsune Tanimoto, Katsuyuki Kiura

    Molecular cancer research : MCR   11 ( 2 )   140 - 8   2013年2月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1158/1541-7786.MCR-12-0401

    Web of Science

    PubMed

    researchmap

  • Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. 国際誌

    Katsuyuki Hotta, Etsuji Suzuki, Massimo Di Maio, Paolo Chiodini, Yoshiro Fujiwara, Nagio Takigawa, Eiki Ichihara, Martin Reck, Christian Manegold, Lothar Pilz, Akiko Hisamoto-Sato, Masahiro Tabata, Mitsune Tanimoto, Frances A Shepherd, Katsuyuki Kiura

    Lung cancer (Amsterdam, Netherlands)   79 ( 1 )   20 - 6   2013年1月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.lungcan.2012.10.007

    Web of Science

    PubMed

    researchmap

  • Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. 国際誌

    Toshio Kubo, Nagio Takigawa, Masahiro Osawa, Daijiro Harada, Takashi Ninomiya, Nobuaki Ochi, Eiki Ichihara, Hiromichi Yamane, Mitsune Tanimoto, Katsuyuki Kiura

    Cancer science   104 ( 1 )   78 - 84   2013年1月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1111/cas.12045

    Web of Science

    PubMed

    researchmap

  • A definite case of (L)-carbocisteine-induced pneumonia with CATCH22 syndrome.

    Kenichiro Kudo, Eiki Ichihara, Akiko Hisamoto, Katsuyuki Hotta, Nobuaki Miyahara, Yasushi Tanimoto, Sadaharu Akagi, Katsuya Kato, Mitsune Tanimoto, Katsuyuki Kiura

    Internal medicine (Tokyo, Japan)   52 ( 1 )   97 - 100   2013年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.2169/internalmedicine.52.7882

    Web of Science

    PubMed

    researchmap

  • Influence of the timing of tumor regression after the initiation of chemoradiotherapy on prognosis in patients with limited-disease small-cell lung cancer achieving objective response. 国際誌

    Masanori Fujii, Katsuyuki Hotta, Nagio Takigawa, Akiko Hisamoto, Eiki Ichihara, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura

    Lung cancer (Amsterdam, Netherlands)   78 ( 1 )   107 - 11   2012年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.lungcan.2012.07.001

    Web of Science

    PubMed

    researchmap

  • JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation. 国際誌

    Daijiro Harada, Nagio Takigawa, Nobuaki Ochi, Takashi Ninomiya, Masayuki Yasugi, Toshio Kubo, Hiromasa Takeda, Eiki Ichihara, Kadoaki Ohashi, Saburo Takata, Mitsune Tanimoto, Katsuyuki Kiura

    Cancer science   103 ( 10 )   1795 - 802   2012年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1111/j.1349-7006.2012.02363.x

    Web of Science

    PubMed

    researchmap

  • Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402. 国際誌

    Naoyuki Nogami, Katsuyuki Hotta, Yoshihiko Segawa, Nagio Takigawa, Shinobu Hosokawa, Isao Oze, Masanori Fujii, Eiki Ichihara, Takuo Shibayama, Atsuhiko Tada, Noboru Hamada, Masatoshi Uno, Akihiko Tamaoki, Shoichi Kuyama, Genyo Ikeda, Masahiro Osawa, Saburo Takata, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura

    Acta oncologica (Stockholm, Sweden)   51 ( 6 )   768 - 73   2012年7月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.3109/0284186X.2011.648342

    Web of Science

    PubMed

    researchmap

  • [Case report: Two cases of adult Langerhans cell histiocytosis treated with systemic chemotherapy].

    Kenichiro Kudo, Eiki Ichihara, Akiko Hisamoto, Katsuyuki Hotta, Koichi Ichimura, Yasushi Tanimoto, Masahiro Tabata, Nagio Takigawa, Mitsune Tanimoto, Katsuyuki Kiura

    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine   101 ( 5 )   1386 - 8   2012年5月

    　詳細を見る

    記述言語：日本語   掲載種別：研究論文（学術雑誌）  

    PubMed

    researchmap

  • Favorable response of heavily treated Wilms' tumor to paclitaxel and carboplatin. 国際誌

    Saeko Ozaki, Nagio Takigawa, Eiki Ichihara, Katsuyuki Hotta, Isao Oze, Etsuko Kurimoto, Soichiro Fushimi, Tetsuya Ogino, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura

    Onkologie   35 ( 5 )   283 - 6   2012年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1159/000338532

    Web of Science

    PubMed

    researchmap

  • Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades. 国際誌

    Nobuaki Ochi, Katsuyuki Hotta, Nagio Takigawa, Isao Oze, Yoshiro Fujiwara, Eiki Ichihara, Akiko Hisamoto, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura

    PloS one   7 ( 8 )   e42798   2012年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1371/journal.pone.0042798

    Web of Science

    PubMed

    researchmap

  • W2-2 気管内チューブを用いたEBUS-TBNAの使用経験(EBUS-TBNA,ワークショップ2,第35回日本呼吸器内視鏡学会学術集会)

    南 大輔, 瀧川 奈義夫, 村上 斗司, 谷口 暁彦, 市原 英基, 久本 晃子, 堀田 勝幸, 宮原 信明, 谷本 安, 田端 雅彦, 金廣 有彦, 谷本 光音, 木浦 勝行

    気管支学   34   S123   2012年

    　詳細を見る

    記述言語：日本語   出版者・発行元：特定非営利活動法人 日本呼吸器内視鏡学会  

    DOI： 10.18907/jjsre.34.Special_S123_2

    CiNii Article

    researchmap

  • Targeting angiogenesis in cancer therapy.

    Eiki Ichihara, Katsuyuki Kiura, Mitsune Tanimoto

    Acta medica Okayama   65 ( 6 )   353 - 62   2011年12月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Web of Science

    PubMed

    researchmap

  • Establishment of pemetrexed-resistant non-small cell lung cancer cell lines. 国際誌

    Dan Zhang, Nobuaki Ochi, Nagio Takigawa, Yasushi Tanimoto, Yanyan Chen, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura

    Cancer letters   309 ( 2 )   228 - 35   2011年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.canlet.2011.06.006

    Web of Science

    PubMed

    researchmap

  • Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. 国際誌

    Kammei Rai, Nagio Takigawa, Sachio Ito, Hiromi Kashihara, Eiki Ichihara, Tatsuji Yasuda, Kenji Shimizu, Mitsune Tanimoto, Katsuyuki Kiura

    Molecular cancer therapeutics   10 ( 9 )   1720 - 7   2011年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1158/1535-7163.MCT-11-0220

    Web of Science

    PubMed

    researchmap

  • Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review. 国際誌

    Katsuyuki Hotta, Katsuyuki Kiura, Yoshiro Fujiwara, Nagio Takigawa, Akiko Hisamoto, Eiki Ichihara, Masahiro Tabata, Mitsune Tanimoto

    PloS one   6 ( 11 )   e26646   2011年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1371/journal.pone.0026646

    Web of Science

    PubMed

    researchmap

  • Early palliative care in non-small-cell lung cancer. 国際誌

    Eiki Ichihara, Junji Matsuoka, Katsuyuki Kiura

    The New England journal of medicine   363 ( 23 )   2263; author reply 2264-5 - 2263   2010年12月

    　詳細を見る

  • 異種移植モデルにおいて高用量ゲフィチニブは肝細胞成長因子(HGF)誘発性のゲフィチニブ耐性を克服する(High-dose gefitinib overcomes the gefitinib resistance induced by hepatocyte growth factor (HGF) in a xenograft model)

    Kashihara Hiromi, Ichihara Eiki, Takata Saburo, Ohashi Kadoaki, Kubo Toshio, Takeda Hiromasa, Fujii Masanori, Takigawa Nagio, Tanimoto Mitsune, Kiura Katsuyuki

    日本呼吸器学会雑誌   48 ( 増刊 )   407 - 407   2010年3月

    　詳細を見る

    記述言語：英語   出版者・発行元：(一社)日本呼吸器学会  

    researchmap

  • Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice. 国際誌

    Kadoaki Ohashi, Nagio Takigawa, Masahiro Osawa, Eiki Ichihara, Hiromasa Takeda, Toshio Kubo, Seiki Hirano, Tadashi Yoshino, Minoru Takata, Mitsune Tanimoto, Katsuyuki Kiura

    Cancer research   69 ( 17 )   7088 - 95   2009年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1158/0008-5472.CAN-08-4205

    Web of Science

    PubMed

    researchmap

  • Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. 国際誌

    Eiki Ichihara, Kadoaki Ohashi, Nagio Takigawa, Masahiro Osawa, Atsuko Ogino, Mitsune Tanimoto, Katsuyuki Kiura

    Cancer research   69 ( 12 )   5091 - 8   2009年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1158/0008-5472.CAN-08-4204

    Web of Science

    PubMed

    researchmap

  • Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation In vivo

    Eiki Ichihara, Kadoaki Ohashi, Nagio Takigawa, Masahiro Osawa, Atsuko Ogino, Mitsune Tanimoto, Katsuyuki Kiura

    CANCER RESEARCH   69 ( 12 )   5091 - 5098   2009年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1158/0008-5472.CAN-08-4204

    Web of Science

    researchmap

  • 喫煙非関連肺癌のマウスモデルにおける腫瘍形成に対するバンデタニブの化学予防作用(Chemopreventive effect of vandetanib on tumorigenesis in a mouse model of non-smoking related lung cancer)

    Kubo Toshio, Ohashi Kadoaki, Osawa Masahiro, Takeda Hiromasa, Ichihara Eiki, Fujii Masanori, Kashihara Hiromi, Takigawa Nagio, Tanimoto Mitsune, Kiura Katsuyuki

    日本呼吸器学会雑誌   47 ( 増刊 )   341 - 341   2009年5月

    　詳細を見る

    記述言語：英語   出版者・発行元：(一社)日本呼吸器学会  

    researchmap

  • Synchronous pulmonary MALT lymphoma and pulmonary adenocarcinoma after metachronous gastric MALT lymphoma and gastric adenocarcinoma. 国際誌

    Eiki Ichihara, Masahiro Tabata, Nagio Takigawa, Yumiko Sato, Eisaku Kondo, Motoi Aoe, Katsuyuki Kiura, Mitsune Tanimoto

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer   3 ( 11 )   1362 - 3   2008年11月

    　詳細を見る

  • Vandetanib処置後の肺腺癌細胞株のEGFR T 790M変異の出現(Emergence of The EGFR T 790 M Mutation in A Lung Adenocarcinoma Cell Line after Vandetanib Treatment)

    Ichihara Eiki, Ohashi Kadoaki, Takigawa Nagio, Ogino Atsuko, Tanimoto Mitsune, Kiura Katsuyuki

    日本呼吸器学会雑誌   46 ( 増刊 )   354 - 354   2008年5月

    　詳細を見る

    記述言語：英語   出版者・発行元：(一社)日本呼吸器学会  

    researchmap

  • Pseudoprogression of lung cancer after concomitant chemoradiotherapy. 国際誌

    Eiki Ichihara, Katsuyuki Kiura, Nagio Takigawa, Masako Omori, Motoi Aoe, Mitsune Tanimoto, Hiroshi Date

    Japanese journal of clinical oncology   38 ( 2 )   140 - 2   2008年2月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1093/jjco/hym166

    Web of Science

    PubMed

    researchmap

  • [Coinfection with Mycoplasma pneumoniae and Chlamydophila pneumoniae in a middle-aged adult].

    Toshio Kubo, Nagio Takigawa, Yasushi Tanimoto, Eiki Ichihara, Masahiro Tabata, Nobuaki Miyahara, Arihiko Kanehiro, Katsuyuki Kiura, Mitsune Tanimoto

    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society   45 ( 10 )   808 - 11   2007年10月

    　詳細を見る

    記述言語：日本語   掲載種別：研究論文（学術雑誌）  

    A 47-year-old man who suffered from fever and dry cough visited a local clinic. His symptoms temporarily improved with oral administration of ciprofloxacin, however, he was admitted to our hospital because of exacerbation. IgM antibody for Mycoplasma pneumoniae was positive and IgM antibody titer for Chlamydophila pneumoniae showed a high value of 7.12 index. Thus, coinfection was diagnosed. The findings of chest X-ray and computed tomography were compatible with atypical pneumonia. Clarithromycin improved his condition, and 10 weeks later, antibody values for Mycoplasma pneumoniae by the particle agglutination test decreased from 10,240 times to 640 times and those by the complement-fixation test also decreased from 1024 times to 256 times. The IgM antibody for Chlamydophila pnetumoniae decreased to 0.13. This is the first case developing coinfection with Mycoplasma pneumoniae and Chlamydophila pneumoniae in a middle-aged patient to date.

    PubMed

    researchmap

  • [Azygos vein aneurysm occurring simultaneously with hemoptysis].

    Eiki Ichihara, Masahiro Kaneko, Hiroshi Fujii, Kyousuke Ishihara

    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society   45 ( 6 )   479 - 82   2007年6月

    　詳細を見る

    記述言語：日本語   掲載種別：研究論文（学術雑誌）  

    A 64-year-old man was admitted with hemoptysis. A chest X-ray showed a well-defined round nodule at the right tracheobronchial angle. Enhanced computed tomography revealed the superior vena cava to be completely occluded while the azygos vein was also observed to have formed an aneurysm. Bronchoscopy showed the submucosal bronchial vessels at the right second carina to be markedly dilated, and thus considered them to be the likely cause of hemoptysis. Based on the above findings, we considered the following events as the most likely to have taken place: The superior vena cava was completely occluded due to the long-term placement of a pacemaker. The blood flow of head and upper limbs could not sufficiently return to the heart, but instead flowed into the azygos vein via the collateral circulation. This resulted in both the formation of the azygos vein aneurysm and an elevated venous pressure of the bronchial vein. Due to this pressure elevation, the bronchial vein and small vessels had both ruptured, thereby inducing the onset of hemoptysis.

    PubMed

    researchmap

  • [Characteristics of asthma patients who need repeated hospitalization; frequency of use of systemic corticosteroids, emergency and unscheduled hospital visits and habitual use of sleeping pills].

    Masahiro Kaneko, Kyousuke Ishihara, Takashi Hajiro, Hiroshi Fujii, Eiki Ichihara

    Arerugi = [Allergy]   56 ( 5 )   477 - 84   2007年5月

    　詳細を見る

    記述言語：日本語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: This study aimed to analyze the characteristics of frequently hospitalized patients. METHODS: The clinical characteristics of 310 cases having hospitalization episodes (206 patients) for asthma attack analyzed retrospectively based on their clinical records. RESULTS: Nineteen out of the 206 patients were hospitalized more than just three times during the study period. Mean age (once hospitalization group 50.0+/-1.5 y.o., twice- 53.0+/-2.6 y.o., > or = 3 times- 56.6+/-2.0 y.o., p=0.02) and the ratio of female (once- 55.2%, twice- 61.5%, > or = 3 times- 78.9%, p=0.04) were higher among the groups. The frequency of use of systemic corticosteroids (once- 23.6%, twice- 50.0%, > or = 3 times- 59.8%, p<0.01), emergency and unscheduled hospital visits (once- 0.5+/-0.1 times/6M, twice- 1.3+/-0.3 times/6M, > or = 3 times- 2.7+/-0.2 times/6M, p<0.01), and habitual use of sleeping pills (once- 11.8%, twice- 30.8%, > or = 3 times- 47.4%, p<0.01) were significantly different among the groups. CONCLUSION: Among the patients who need repeated hospitalization, the frequency of use of systemic corticosteroids, emergency and unscheduled hospital visits, and habitual use of sleeping pills were higher.

    PubMed

    researchmap

  • Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells. 国際誌

    Nagio Takigawa, Masami Takeyama, Toshiyuki Kozuki, Takuo Shibayama, Akiko Hisamoto, Katsuyuki Kiura, Atsuhiko Tada, Katsuyuki Hotta, Shigeki Umemura, Kadoaki Ohashi, Yoshiro Fujiwara, Saburo Takata, Eiki Ichihara, Masahiro Osawa, Masahiro Tabata, Mitsune Tanimoto, Kiyoshi Takahashi

    Oncology reports   17 ( 5 )   983 - 7   2007年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Web of Science

    PubMed

    researchmap

▼全件表示

書籍等出版物

  • 新臨床腫瘍学（改訂第7版）

    日本臨床腫瘍学会（ 担当： 分担執筆 ,  範囲: 分子標的治療薬概論）

    南江堂  2024年2月  （ ISBN:9784524204267 ）

    　詳細を見る

    総ページ数：xx, 767p   記述言語：日本語

    CiNii Books

    researchmap

  • 肺癌薬物療法レジメン Expert’s Choice

    （ 担当： 分担執筆 ,  範囲: Chapter 3 非小細胞肺癌 非扁平上皮癌（IV期）PD-L1≧50%（PS良好）PD-L1≧50%（PS不良））

    メジカルビュー  2022年3月  （ ISBN:9784758318181 ）

    　詳細を見る

  • 見る診るわかる!胸部画像診断

    市原英基, 木浦勝行（ 担当： 分担執筆 ,  範囲: 大細胞癌、腫瘍塞栓症）

    中外医学社  2021年8月  （ ISBN:9784498013803 ）

    　詳細を見る

    総ページ数：299p   記述言語：日本語

    CiNii Books

    researchmap

  • 新臨床腫瘍学（改訂６版） : がん薬物療法専門医のために

    市原英基（ 担当： 分担執筆 ,  範囲: 分子標的治療薬概論）

    南江堂  2021年5月  （ ISBN:9784524227396 ）

    　詳細を見る

    総ページ数：xix, 757p   記述言語：日本語

    CiNii Books

    researchmap

  • COVID-19の病態・診断・治療 : 現場の知恵とこれからの羅針盤

    市原英基（ 担当： 分担執筆 ,  範囲: 肺癌とCOVID-19）

    医学書院  2021年1月  （ ISBN:9784260045858 ）

    　詳細を見る

    総ページ数：xiv, 225p   記述言語：日本語

    CiNii Books

    researchmap

  • 癌と化学療法 第４７巻第１２号（２０２０年１２月） 特集・ＣＯＶＩＤ－１９パンデミックとがん医療への影響

    工藤健一郎, 市原英基（ 担当： 分担執筆 ,  範囲: COVID-19における肺炎）

    2020年12月 

    　詳細を見る

  • コロナ禍におけるがん患者・家族への支援 看護技術2020年12月号

    西達也, 市原英基（ 担当： 分担執筆 ,  範囲: 外来での化学療法、緩和医療、化学療法を継続するか否かを迷う患者・家族への支援と感染対策のために）

    2020年12月 

    　詳細を見る

  • 肺がん化学療法副作用マネジメント

    市原英基（ 担当： 分担執筆 ,  範囲: 7 神経 (2) 末梢神経障害）

    メジカルビュー社  2019年7月  （ ISBN:9784758318051 ）

    　詳細を見る

    総ページ数：395p   記述言語：日本語

    CiNii Books

    researchmap

  • カレントセラピー バイオマーカーを用いたがんの診断と治療

    渡邉洋美, 市原英基（ 担当： 分担執筆 ,  範囲: ALK融合遺伝子・ROS1融合遺伝子におけるコンパニオン診断薬）

    ライフメディアコム  2018年9月 

    　詳細を見る

  • 新臨床腫瘍学(改訂第5版): がん薬物療法専門医のために

    市原英基（ 担当： 分担執筆 ,  範囲: 分子標的治療薬概論）

    南江堂  2018年7月  （ ISBN:4524237887 ）

    　詳細を見る

    総ページ数：840   記述言語：日本語

    CiNii Books

    ASIN

    researchmap

  • 肺癌診療Q&A : 一つ上を行く診療の実践

    市原英基, 木浦勝行（ 担当： 分担執筆 ,  範囲: 薬物療法副作用への対応）

    中外医学社  2017年10月  （ ISBN:9784498131002 ）

    　詳細を見る

    総ページ数：vii, 521p   記述言語：日本語

    CiNii Books

    researchmap

  • 肺癌診療Q&A : 一つ上を行く診療の実践

    市原英基（ 担当： 分担執筆 ,  範囲: G-CSFの使用の適応）

    中外医学社  2017年10月  （ ISBN:9784498131002 ）

    　詳細を見る

    総ページ数：vii, 521p   記述言語：日本語

    CiNii Books

    researchmap

  • 内科學 第11版

    市原英基、二宮崇、久保寿夫、大橋圭明、木浦勝行（ 担当： 分担執筆 ,  範囲: 呼吸器系の疾患 縦隔疾患）

    朝倉書店  2017年3月  （ ISBN:9784254322712 ）

    　詳細を見る

    総ページ数：5冊   記述言語：日本語

    CiNii Books

    researchmap

  • エビデンスに基づいた癌化学療法ハンドブック2012

    加藤有加, 市原英基, 木浦勝行（ 担当： 分担執筆 ,  範囲: Elrotinib）

    2012年8月 

    　詳細を見る

  • 医学のあゆみ 肺癌UPDATE

    市原英基、木浦勝行（ 担当： 分担執筆 ,  範囲: IV期非小細胞肺癌におけるセカンドライン・サードラインのエビデンスと今後の展望）

    医歯薬出版株式会社  2012年3月 

    　詳細を見る

  • インフォームドコンセントのための図説シリーズ 肺がん 抗悪性腫瘍薬 改訂4版

    柳瀬香葉, 市原英基, 木浦勝行（ 担当： 分担執筆 ,  範囲: セカンドライン，サードライン化学療法の定義）

    医薬ジャーナル社  2011年11月 

    　詳細を見る

  • がんの新しいバイオマーカー/予測因子による個別化医療時代に求められる抗がん剤開発

    市原英基（ 担当： 分担執筆 ,  範囲: がんバイオマーカー／予測因子）

    技術情報協会  2011年6月 

    　詳細を見る

  • がんの分子標的と治療薬事典

    市原英基（ 担当： 分担執筆 ,  範囲: EpCAM, Adecatumumab）

    羊土社  2010年10月  （ ISBN:9784758120166 ）

    　詳細を見る

    総ページ数：346p   記述言語：日本語

    CiNii Books

    researchmap

  • 腫瘍内科

    市原英基, 木浦勝行（ 担当： 分担執筆 ,  範囲: 小分子物質と抗体の違い）

    科学評論社  2010年6月 

    　詳細を見る

▼全件表示

MISC

▼全件表示

講演・口頭発表等

  • 小細胞肺がんの薬物療法（臓器別ワークショップ） 招待

    市原英基

    第61回日本癌治療学会学術集会  2023年10月20日 

    　詳細を見る

    開催年月日： 2023年10月19日 - 2023年10月21日

    researchmap

  • 肺癌薬物療法の更なる治療効果を 目指した基礎・臨床研究（篠井・河合賞受賞記念講演） 招待

    市原英基

    第62回日本肺癌学会学術集会  2021年11月27日 

    　詳細を見る

    開催年月日： 2021年11月26日 - 2021年11月28日

    記述言語：日本語   会議種別：公開講演，セミナー，チュートリアル，講習，講義等  

    researchmap

  • 肺小細胞がんの薬剤開発 分子標的治療開発からの教訓と 免疫チェックポイント阻害剤への期待（シンポジウム）

    市原英基

    第62回日本肺癌学会学術集会  2021年11月26日 

    　詳細を見る

    開催年月日： 2021年11月26日 - 2021年11月28日

    記述言語：日本語   会議種別：シンポジウム・ワークショップ パネル（指名）  

    researchmap

  • がん患者と コロナワクチン

    市原英基

    がん患者学会2021  2021年8月22日 

    　詳細を見る

    開催年月日： 2021年8月22日

    記述言語：日本語   会議種別：公開講演，セミナー，チュートリアル，講習，講義等  

    researchmap

  • 間質性肺炎合併症例に対する 細胞傷害性抗がん剤をどう考えるか（シンポジウム）

    市原英基

    第61回日本呼吸器学会学術集会  2021年4月25日 

    　詳細を見る

    開催年月日： 2021年4月23日 - 2021年4月25日

    記述言語：日本語   会議種別：シンポジウム・ワークショップ パネル（指名）  

    researchmap

  • Phase I/II study of osimertinib in EGFR exon 20 insertion mutations in non-small cell lung cancer patients: AEX20.（口演）

    Eiki Ichihara, Hiroyuki Yasuda, Yuta Takashima, Yoshitaka Zenke, Shinji Takeuchi, Masahiro Morise, Katsuyuki Hotta, Mineyoshi Sato, Shingo Matsumoto, Azusa Tanimoto, Reiko Matsuzawa, Katuyuki Kiura, Hideki Terai, Shinnosuke Ikemura, Ryo Takemura, Koichi Goto, Kenzo Soejima

    AACR Annual Meeting 2021  2021年4月10日 

    　詳細を見る

    開催年月日： 2021年4月10日 - 2021年4月15日

    記述言語：英語   会議種別：ポスター発表  

    researchmap

  • 免疫チェックポイント阻害薬が有効なEGFR遺伝子変異陽性肺癌の特徴（口演）

    市原 英基, 原田大二郎, 井上 考司, 柴山 卓夫, 細川 忍, 岸野 大蔵, 張田 信吾, 越智 宣昭, 小田 尚廣, 原 尚史, 堀田 勝幸, 前田 嘉信, 木浦 勝行

    第61回日本肺癌学会学術集会  2020年11月14日 

    　詳細を見る

    開催年月日： 2020年11月12日 - 2020年11月14日

    記述言語：日本語   会議種別：口頭発表（一般）  

    researchmap

  • EGFR-TKIと血管新生阻害薬の併用 今後の展望（ワークショップ）

    市原英基

    第61回日本肺癌学会学術集会  2020年11月13日 

    　詳細を見る

    開催年月日： 2020年11月12日 - 2020年11月14日

    記述言語：日本語   会議種別：シンポジウム・ワークショップ パネル（指名）  

    researchmap

  • Resistant mechanisms to ALK TKIs（シンポジウム）

    市原英基

    第59回日本肺癌学会学術集会  2018年11月30日 

    　詳細を見る

    開催年月日： 2018年11月29日 - 2018年12月1日

    記述言語：日本語  

    researchmap

  • I. 一部改訂について: 「泌尿器がん」 「肉腫」 「呼吸器がん」の 一部改訂について

    市原英基, 三浦裕司

    第55回日本癌治療学会学術集会  2017年10月21日 

    　詳細を見る

    開催年月日： 2017年10月20日 - 2017年10月22日

    記述言語：日本語  

    researchmap

  • Significance of repeating rebiopsy for detecting T790M mutation（口演）

    第58回日本肺癌学会学術集会  2017年10月14日 

    　詳細を見る

    開催年月日： 2017年10月14日 - 2017年10月15日

    記述言語：日本語   会議種別：口頭発表（一般）  

    researchmap

  • Possibility of combination therapy using EGFR TKIs（シンポジウム） 招待

    市原英基

    第15回日本臨床腫瘍学会学術集会  2017年7月27日 

    　詳細を見る

    開催年月日： 2017年7月27日 - 2017年7月29日

    記述言語：英語   会議種別：シンポジウム・ワークショップ パネル（指名）  

    researchmap

  • 英文化にむけて

    市原英基

    第54回日本癌治療学会学術集会  2016年10月21日 

    　詳細を見る

    開催年月日： 2016年10月20日 - 2016年10月22日

    記述言語：日本語  

    researchmap

  • COVID-19禍における肺癌診療（シンポジウム）

    市原英基

    第63回日本肺癌学会学術集会  2022年12月1日 

    　詳細を見る

  • 肺がん臨床試験はどれくらいの実診療患者をカバーできるのか（シンポジウム）

    市原英基

    第62回日本呼吸器学会学術集会  2022年4月22日 

    　詳細を見る

▼全件表示

受賞

  • 篠井・河合賞

    2021年11月   日本肺癌学会  

    　詳細を見る

  • 楷の木賞特別賞

    2021年3月   岡山大学病院  

    　詳細を見る

  • 肺癌研究助成

    2020年11月   日本肺癌学会  

    　詳細を見る

  • プロジェクト未来

    2019年12月   日本対がん協会  

    　詳細を見る

  • 海外留学助成

    2013年12月   上原記念生命科学財団  

    　詳細を見る

  • 岡山医学会賞（山田賞）

    2010年6月   岡山医学会  

    　詳細を見る

  • 第二内科同門会賞

    2009年11月   第二内科同門会  

    　詳細を見る

  • 若手奨励賞

    2005年10月   日本内科学会 中国支部会  

    　詳細を見る

▼全件表示

共同研究・競争的資金等の研究

  • 免疫チェックポイント阻害薬の重篤副作用を予測するバイオマーカーの同定

    2023年

    日本医療研究開発機構  医薬品等規制調和・評価研究事業 

    河野 隆志, 市原 英基, 谷岡 真樹, 濱野 裕章, 白石 航也, 吉田 達哉, 下田 由季子, 本間 義崇, 平野 秀和, 庄司 広和, 緒方 大

    　 詳細を見る

    担当区分：研究分担者 

    researchmap

  • SHP2による薬剤toleranceを標的とした肺がん根治的治療の開発

    研究課題/領域番号：21K08179  2021年04月 - 2024年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    市原 英基, 久保 寿夫

    　 詳細を見る

    配分額：4160000円 （ 直接経費：3200000円 、 間接経費：960000円 ）

    肺がんは、様々な原因遺伝子異常に対応した分子標的薬により腫瘍が著明に縮小するが根治に至らない．これは一部のがん細胞（drug tolerant細胞）が残存し後に薬剤耐性となることが大きな要因である．SHP2（Src homology region 2 domain-containing phosphatase） は種々のがん増殖シグナルを下流に伝達する重要なチロシンホスファターゼであるが、申請者らは、このSHP2を阻害するとtolerant細胞の残存を抑制できる可能性を見出した．本研究では、様々なタイプの遺伝子異常を持つ肺がんでSHP2阻害によるtolerant細胞抑制効果を確認し、tolerant細胞におけるSHP2シグナルの重要性を明らかにする．研究の方法として、皮下腫瘍移植モデルを用い、1) SHP2阻害薬による腫瘍残存抑制効果の確認、2) 残存腫瘍の網羅的解析（受容体チロシンリン酸化アレイ・遺伝子発現パネル解析）によるSHP2を介したtolerant細胞残存メカニズムの解明を行う．将来的にSHP2シグナル経路を標的とした、より根治性の高い治療開発につなげることを目標とする．本年度はマウス皮下腫瘍モデルを用い、EGFR・ALK・ROS1遺伝子異常を持つ肺癌皮下腫瘍に対するSHP2阻害薬と各遺伝子異常を標的とした薬剤（EGFR阻害薬・ALK阻害薬・ROS1阻害薬）との併用効果を確認した.

    researchmap

  • SHP2シグナル経路を標的としたEGFR/ALK肺がんの根治的新規肺がん治療法の開発

    2020年11月 - 2021年10月

    公益財団法人岡山医学振興会  医学研究助成

    　 詳細を見る

    担当区分：研究代表者 

    researchmap

  • SHP2を標的としたEGFR/ALK/ROS1肺がんにおける根治的新規治療法の開発

    2020年10月 - 2023年03月

    日本肺癌学会  肺癌研究助成

    市原英基

    　 詳細を見る

    担当区分：研究代表者 

    researchmap

  • EGFR/ALK変異陽性肺がんにおけるSHP2シグナル経路を標的とする根治的新規肺がん治療法の開発

    2020年10月 - 2021年09月

    公益財団法人両備檉園記念財団  研究助成

    市原英基

    　 詳細を見る

    担当区分：研究代表者 

    researchmap

  • EGFR遺伝子変異陽性肺がん分子標的治療におけるtolerant細胞を標的とした 根治的新規肺がん治療法の開発

    2019年10月 - 2020年09月

    公益財団法人 日本対がん協会  「プロジェクト未来」研究助成

    　 詳細を見る

    担当区分：研究代表者 

    researchmap

  • 特発性肺線維症合併進行非小細胞肺癌に対する標準治療開発に関する研究

    2019年04月 - 2021年03月

    AMED  革新的がん医療実用化研究事業 

    　 詳細を見る

    担当区分：研究分担者 

    researchmap

  • 上原記念生命科学財団 海外留学助成

    2013年12月 - 2014年11月

    上原記念生命科学財団 

    　 詳細を見る

  • ＡＬＫ遺伝子変異陽性肺癌に対するＡＬＫ阻害薬と血管新生阻害薬の併用効果の検討

    研究課題/領域番号：24790813  2012年04月 - 2013年03月

    日本学術振興会  科学研究費助成事業 若手研究(B)  若手研究(B)

    市原 英基

    　 詳細を見る

    配分額：4290000円 （ 直接経費：3300000円 、 間接経費：990000円 ）

    1. ALK 遺伝子変異陽性肺癌に対するALK 阻害薬＋血管新生阻害薬の有効性の検討 我々は、ALK融合遺伝子を持つ肺癌細胞株であるH2228およびABC-11を用いて、ALK阻害薬であるAF802（CH5424802）の持続的暴露を行うことで、AF802耐性株であるH2228CHRおよびABC11CHRを樹立した。親株であるH2228およびABC-11はAF802に高い感受性を示す(IC50: H2228 0.030±0.020μM, ABC11 0.32± 0.087μM)のに対し、H2228CHR・ABC-11CHRはAF802に高い耐性を示した(IC50: H2228CHR 3.9±0.84μM, ABC-11CHR 5.3±0.91 μM)。しかし、これら細胞株に対して血管新生阻害薬であるbevacizumabはin vitroでの効果を認めなった。
    2. ALK 遺伝子変異陽性肺癌に対するALK 阻害薬＋EGFR 阻害薬の有効性の検討
    上記、H2228CHRはALKだけでなくEGFRが活性化していることをwesernblottingにて証明した。H2228CHRに対するAF802単剤での細胞増殖率は87%であったのに対し、EGFR阻害薬（erlotinib）+ AF802の併用では47%と有意に増殖を抑制していた。
    3. EGFR 遺伝子変異陽性肺癌に対するEGFR 阻害薬＋血管新生阻害薬の有効性の検討
    EGFR遺伝子変異を要する肺癌細胞株H1975のゼノグラフトを作製し、腫瘍抑制効果を検討した。EGFR阻害薬であるBIBW2992+cetuximabの2剤併用療法と比較し、血管新生阻害薬であるbevacizumabを加えた3剤併用療法で腫瘍縮小効果が強い傾向を認めた。

    researchmap

  • 遺伝子改変マウスを利用したＥＧＦＲ遺伝子変異陽性肺癌の基礎的臨床的検討

    研究課題/領域番号：23390221  2011年04月 - 2015年03月

    日本学術振興会  科学研究費助成事業 基盤研究(B)  基盤研究(B)

    木浦 勝行, 瀧川 奈義夫, 堀田 勝幸, 高田 穣, 中別府 雄作, 吉野 正, 市原 英基

    　 詳細を見る

    配分額：19500000円 （ 直接経費：15000000円 、 間接経費：4500000円 ）

    ① EGFR遺伝子改変マウスを使用し，afatinib (非可逆性TKI), everolimus (mTOR阻害薬), AZD1480 (JAK-1/2 阻害薬)の抗腫瘍効果を明らかにした。② マウス異種移植モデルで，T790Mを有する耐性細胞に対してafatinib + cetuximab + bevacizumab併用療法は，持続する病理学的完全奏効をもたらすことを証明した。③ Ogg1ホモノックアウトマウスに高用量タバコ特異的ニトロサミン（NNK）投与で9.3%に早期発癌を肺に認めたが，低用量では発癌を認めず，上皮成長因子受容体(EGFR)遺伝子異常との関連は不明である。

    researchmap

  • 含鉄蛋白質に含まれるラジウムの体内被曝による悪性中皮腫発生機序に関する基礎的研究

    研究課題/領域番号：23659432  2011年 - 2012年

    日本学術振興会  科学研究費助成事業 挑戦的萌芽研究  挑戦的萌芽研究

    木浦 勝行, 瀧川 奈義夫, 市原 英基, 中村 栄三, 吉野 正, 高田 穣

    　 詳細を見る

    配分額：3640000円 （ 直接経費：2800000円 、 間接経費：840000円 ）

    健常雄性 Slc: Wistar ラット 10 匹に鉄およびキレート剤を腹腔内へ反復投与し,5 匹で悪性腹膜中皮腫を認めたが,コントロール群,キレート剤投与群では認めなった。免疫染色(Calretinin, CEA 染色),電子顕微鏡による観察を行い,いずれも上皮型中皮腫であることを確認した。また,DNA 酸化損傷マーカーである 8-hydroxy-2-deoxyguanosine による免疫染色は陽性であり,従来の学説は確認された。ラジウムを含む微量元素を最終解析中である。

    researchmap

  • 上皮成長因子受容体遺伝子改変マウスを利用した肺癌化学予防に関する基礎的研究

    研究課題/領域番号：19590895  2007年 - 2008年

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    木浦 勝行, 瀧川 奈義夫, 高田 穣, 吉野 正, 大橋 圭明, 頼 冠明, 市原 英基, 高田 三郎, 大澤 昌宏, 武田 洋昌, 藤井 昌学, 久保 寿夫, 柏原 宏美, 原田 大二郎, 越智 宣昭, 八杉 昌幸

    　 詳細を見る

    配分額：4550000円 （ 直接経費：3500000円 、 間接経費：1050000円 ）

    肺癌の粗死亡数は増加しているが、喫煙率低下に伴い年齢調整死亡率は低下傾向にある。肺癌患者の男性30%、女性70%は非喫煙者である。非喫煙者肺癌の病因探求およびその予防の研究目的で、上皮成長因子受容体(EGFR)遺伝子改変マウスを作製し、非喫煙関連肺癌マウスモデルを樹立した。ヒトEGFR遺伝子改変マウスは5-6週で多発性の異型腺腫様過形成、肺腺癌が出現し、30週前後で腫瘍死する。これらの肺発癌をgefitinibが効果的に予防することを証明した。

    researchmap

▼全件表示

 

担当授業科目

  • 呼吸器系（臓器・系別統合講義） （2025年度） 特別  - その他

  • 腫瘍学 （2025年度） 特別  - その他

  • 臨床老年医学特論 （2025年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学実習 （2025年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学演習 （2025年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学（基本臨床実習） （2025年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学Ｉ（講義・演習） （2025年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学ＩＩ（講義・演習） （2025年度） 特別  - その他

  • 選択制臨床実習（血液・腫瘍・呼吸器内科学） （2025年度） 特別  - その他

  • 呼吸器系（臓器・系別統合講義） （2024年度） 特別  - その他

  • 腫瘍学 （2024年度） 特別  - その他

  • 臨床老年医学特論 （2024年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学実習 （2024年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学演習 （2024年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学（基本臨床実習） （2024年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学Ｉ（演習・実習） （2024年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学Ｉ（講義・演習） （2024年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学ＩＩ（演習・実習） （2024年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学ＩＩ（講義・演習） （2024年度） 特別  - その他

  • 呼吸器系（臓器・系別統合講義） （2023年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学実習 （2023年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学演習 （2023年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学（基本臨床実習） （2023年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学Ｉ（演習・実習） （2023年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学Ｉ（講義・演習） （2023年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学ＩＩ（演習・実習） （2023年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学ＩＩ（講義・演習） （2023年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学（基本臨床実習） （2022年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学（基本臨床実習） （2021年度） 特別  - その他

  • 血液・腫瘍・呼吸器内科学（基本臨床実習） （2020年度） 特別  - その他

▼全件表示

 

社会貢献活動

  • PEACEプロジェクト緩和ケア研修会 ファシリテーター

    役割：講師

    日本緩和医療学会  2024年1月27日

    　詳細を見る

    種別：資格認定講習

    researchmap

  • がん患者団体向け講演「がん患者とコロナワクチン」

    役割：講師

    一般社団法人 全国がん患者団体連合会  がん患者学会2021  2021年8月22日

    　詳細を見る

    種別：講演会

    researchmap

  • 市民公開講座 最新の肺がんのすべて 「肺がんの免疫療法 ーうそと本当ー」

    役割：講師

    独立行政法人国立病院機構 福山医療センター  市民公開講座  2020年2月8日

    　詳細を見る

    種別：対話型集会・市民会議

    researchmap

  • NPO法人 中国四国呼吸器疾患関連事業包括的支援機構（CS-Lung）事務局担当

    役割：運営参加・支援

    NPO法人 中国四国呼吸器疾患関連事業包括的支援機構（CS-Lung）  2018年4月 - 現在

    　詳細を見る

    種別：その他

    researchmap

  • 市民公開講座 自分に合ったがん治療を受けるために～ライフステージ、ライフスタイルに沿った医療、福祉～ 「免疫治療の嘘と本当 ～まず知っておくべきこと～」

    役割：講師

    中国四国広域がんプロ養成コンソーシアム  市民公開講座  2018年1月19日

    　詳細を見る

    種別：対話型集会・市民会議

    researchmap

  • 市民公開講座 ～きっと役立つがんの最新情報～がん診療最前線 「変わり続ける肺がん治療 その最前線」

    役割：講師

    中国四国広域がんプロ養成コンソーシアム  市民公開講座  2017年1月29日

    　詳細を見る

    種別：対話型集会・市民会議

    researchmap

  • がんプロフェッショナル養成プラン 合同演習ファシリテーター

    役割：講師,　助言･指導

    中国四国広域がんプロ養成コンソーシアム  2016年8月26日 - 2016年8月27日

    　詳細を見る

    種別：セミナー・ワークショップ

    researchmap

  • 岡山操山高校 スーパーグローバルハイスクール 課題研究 アドバイザリースタッフ

    役割：コメンテーター

    岡山操山高校  2016年6月1日 - 2016年11月30日

    　詳細を見る

    種別：研究指導

    researchmap

  • PEACEプロジェクト緩和ケア研修会 ファシリテーター

    役割：講師,　助言･指導

    日本緩和医療学会  2013年3月10日 - 2013年3月17日

    　詳細を見る

    種別：資格認定講習

    researchmap

  • PEACEプロジェクト緩和ケア研修会 ファシリテーター

    役割：講師,　助言･指導

    日本緩和医療学会  2013年2月16日 - 2013年2月17日

    　詳細を見る

    種別：資格認定講習

    researchmap

  • 一般市民向け講演 「緩和医療について」

    役割：講師,　運営参加・支援

    野の花プロジェクト  メディカルカフェ （一般市民向け講演）  2012年12月1日

    　詳細を見る

    種別：サイエンスカフェ

    researchmap

  • 看護師向け講演 「緩和ケア」

    役割：講師

    岡山県看護協会 津山支部  出張ミニ講演会  2012年9月1日

    　詳細を見る

    種別：出前授業

    researchmap

  • 一般市民向け講演 「緩和ケア」

    役割：講師

    芳田学区愛育委員会  出張ミニ講演会  2012年8月4日

    　詳細を見る

    種別：出前授業

    researchmap

  • PEACEプロジェクト緩和ケア研修会 ファシリテーター

    役割：講師,　助言･指導

    日本緩和医療学会  2012年7月7日 - 2012年7月8日

    　詳細を見る

    種別：資格認定講習

    researchmap

  • PEACEプロジェクト緩和ケア研修会 ファシリテーター

    役割：講師,　助言･指導

    2012年3月25日

    　詳細を見る

    種別：資格認定講習

    researchmap

  • 一般市民向け講演 「緩和ケア」

    役割：講師

    倉敷市保健所  出張ミニ講演会  2012年1月12日

    　詳細を見る

    種別：出前授業

    researchmap

  • 一般市民向け講演 「緩和ケア」

    役割：講師

    家庭教育学級 めるへん児島  出張ミニ講演会  2011年11月24日

    　詳細を見る

    種別：出前授業

    researchmap

  • 一般市民向け講演 「緩和ケア」

    役割：講師

    岡山県女性教師の会  出張ミニ講演会  2011年8月26日

    　詳細を見る

    種別：出前授業

    researchmap

  • PEACEプロジェクト緩和ケア研修会 ファシリテーター

    役割：講師,　助言･指導

    日本緩和医療学会  2011年7月3日 - 2011年7月4日

    　詳細を見る

    種別：資格認定講習

    researchmap

  • 一般市民向け講演 「緩和医療について」

    役割：講師

    野の花プロジェクト  メディカルカフェ （一般市民向け講演）  2011年6月12日

    　詳細を見る

    種別：サイエンスカフェ

    researchmap

  • 一般市民向け講演 「緩和医療」

    役割：講師

    浅口市愛育委員会  出張ミニ講演会  2011年5月20日

    　詳細を見る

    種別：出前授業

    researchmap

  • 東日本大震災 災害救助活動

    役割：運営参加・支援

    2011年4月15日 - 2011年4月18日

    　詳細を見る

    種別：その他

    researchmap

  • PEACEプロジェクト緩和ケア研修会 ファシリテーター

    役割：講師,　助言･指導

    日本緩和医療学会  2011年3月20日 - 2011年3月21日

    　詳細を見る

    種別：資格認定講習

    researchmap

  • 一般市民向け講演 「緩和医療について」

    役割：講師

    介護老人保健施設 ケアガーデン津山  2011年3月17日

    　詳細を見る

    種別：出前授業

    researchmap

  • 訪問看護師向け講演 「緩和医療」

    役割：講師

    岡山しげい訪問看護ステーション  出張ミニ講演会  2011年1月22日

    　詳細を見る

    種別：出前授業

    researchmap

  • 一般市民向け出張講演 「緩和ケアってなに？」

    役割：講師

    備中保健所 愛育委員  出張ミニ講演会  2010年12月10日

    　詳細を見る

    種別：出前授業

    researchmap

  • 一般市民向け出張講演 「緩和ケア」

    役割：講師

    特別養護老人ホーム かもがわ荘  出張ミニ講演会  2010年7月22日

    　詳細を見る

    種別：出前授業

    researchmap

  • 一般市民向け講演 「緩和医療について」

    役割：講師

    野の花プロジェクト  メディカルカフェ （一般市民向け講演）  2010年7月11日

    　詳細を見る

    種別：サイエンスカフェ

    researchmap

  • 一般市民向け講演「緩和医療」

    役割：講師

    野の花プロジェクト  メディカルカフェ （一般市民向け講演）  2009年10月11日

    　詳細を見る

    種別：サイエンスカフェ

    researchmap

▼全件表示

学術貢献活動

  • 第62回日本呼吸器学会学術講演会 プログラム委員会委員

    役割：企画立案・運営等

    横山彰仁  2021年4月1日 - 現在

    　詳細を見る

    種別：学会・研究会等 

    researchmap

  • 第61回日本肺癌学会学術集会 事務局長

    役割：企画立案・運営等

    木浦勝行  2019年12月1日 - 2021年11月14日

    　詳細を見る

    種別：学会・研究会等 

    researchmap

  • 第15回日本臨床腫瘍学会学術集会 プログラム委員会委員

    役割：企画立案・運営等

    谷本光音  2015年8月1日 - 2017年7月29日

    　詳細を見る

    種別：学会・研究会等 

    researchmap

  • 第48回日本呼吸器学会中国・四国地方会 事務局長

    役割：企画立案・運営等

    木浦勝行  2011年1月1日 - 2012年12月22日

    　詳細を見る

    種別：学会・研究会等 

    researchmap

  • 第17回日本緩和医療学会学術大会 事務局長

    役割：企画立案・運営等

    松岡順治  2010年7月1日 - 2012年6月23日

    　詳細を見る

    種別：学会・研究会等 

    researchmap